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Abstract 
Colorectal cancer (CRC) is a major health problem and cause of morbidity and mortality 
worldwide. The clinical efficacy of oxaliplatin (OXL), a commonly used chemotherapy agent, 
is limited by tumor resistance largely due to reduced drug accumulation. The role of copper 
(Cu) transporters in the transport and pharmacology of OXL is unclear, including Cu uptake 
transporter 1 (CTR1), and efflux transporter Cu+-transporting P-type ATPase ATP7A and 
ATP7B. The project aimed to investigate the contribution of Cu transporters to the uptake and 
cytotoxicity of OXL, and their expression in CRC.  
CRC cells were engineered to overexpress hCTR1 gene (hCTR1/DLD-1 cells) or the empty 
vector as mock control cells to study the uptake and cytotoxicity of OXL. A fluorescent probe 
FDCPt1 was used to visualize the cellular uptake of OXL-derived monofunctional platinum 
bio-transformed products. The expression profile of Cu transporters was characterized in 
colorectal cancer cell lines before evaluating the synergism between Cu chelators and OXL in 
colorectal cancer cells based on their regulation on hCTR1 protein. The expression of copper 
transporters was also investigated in paired patient tumor biopsies. In addition, a colitis model 
of Winnie mouse carrying point mutation of Muc2 gene and a dextran sodium sulphate (DSS)-
induced colonic dysplasia model were used to determine the correlation of Cu transporters 
with these precancerous conditions. 
Overexpression of hCTR1 contributes to OXL cytotoxicity and uptake in recombinant 
colorectal cancer DLD-1 cells, with increased sensitivity and stronger FDCPt1-derived 
fluorescent signals than mock cells.  
 21 
The mRNA of Cu transporters was detected at constantly high levels in colorectal cancer cell 
lines with different origins. hCTR1 protein was expressed abundantly with the expression 
intensity higher than ATP7A or ATP7B across cell lines. Cu chelators, ammonium 
tetrathiomolybdate, and D-penicillamine, and bathocuprione disulphonate up regulated hCTR1 
protein levels and enhanced the cell-killing capacity of OXL in some of CRC cells. 
Human colonic tissues were stained positive for Cu transporters with varying percentage of 
staining between individual patients. Semi-quantitative analysis using de-convolution method 
shows hCTR1 staining seems to be similar between tumor and the matched normal tissues. 
ATP7B expression exhibits a trend towards up regulation in tumor tissues compared to that of 
normal tissues, suggesting this protein may be involved in the development of colonic 
malignancy.  
Chronic intestinal colitis and dysplasia were confirmed histologically in colonic tissues of 
Winnie mice, and DSS-treated Winnie mice, respectively. Mouse Cu transporter 1 (mCTR1) 
was detected in colonic tissues of these animals, but with varying localization and intensity. 
The percentage of mCTR1 staining increased in colonic tissues of Winnie mice, but decreased 
in tissues of dysplasia model compared to that of the normal colon tissues. ATP7A and ATP7B 
expression did not change in colitis tissues but decreased significantly in dysplasia tissues.  
In conclusion, our work demonstrated for the first time the positive involvement of hCTR1 in 
the uptake and cytotoxicity of OXL in some colorectal cancer cells genetically or 
pharmacologically modified to overexpress hCTR1 protein. The abundant expression of 
hCTR1 in human colorectal cancer cells and tumor tissues highlighted again the importance 
of copper in the development of colorectal adenocarcinoma. The altered expression of copper 
transporters in the precancerous colonic tissues of Winnie mice suggests copper homeostasis 
may be disturbed during the chronic progress of colorectal carcinogenesis. 
 22 
Chapter 1 Literature Review 
1.1 Colorectal cancer  
Colorectal cancer (CRC), also known as bowel cancer, is the third most common cancer and 
the fourth most common cause of cancer death globally [1]. In Australia, CRC is the second 
most common cancer with ~14,900 new cases and ~4,000 deaths annually over the past few 
years. These numbers are predicted to continue to increase in the future due to the aging 
population [2]. CRC causes significant economic and social burden in this country, with an 
estimated total health care expenditure of $235 million on this disease in 2001 [3].   
Colorectal cancer is generally classified into three types, namely, sporadic, familial and 
hereditary CRC, accounting for ~80%, 15% and 5% of all cases respectively. The hereditary 
CRC is caused by inherited mutations of certain genes, such as familial adenomatous polyposis 
and hereditary non-polyposis colorectal cancer [4,5]. The TNM system is used clinically for 
staging CRC based on its severity and the spread according to three variables: size and 
extension of the primary tumor (T), nearby lymph nodes that are involved (N), and information 
about distant metastasis (M) [6]. Common diagnostic methods are immunochemical fecal 
occult blood test, sigmoidoscopy, colonoscopy and faecal DNA test.  
Treatment options for CRC mainly include mainly surgery, radiotherapy and chemotherapy. 
Although factors such as the age of the patients and their health status can influence treatment 
options, the final selection of therapy modality is mainly based on the staging of the cancer. 
Although approximately 70-80% newly diagnosed cases are curable by surgery, half of these 
patients still develop incurable relapses after R0 resection [7]. Therefore, chemotherapy is 
required to control the recurrence of CRC by killing the non-visible residual tumor cells after 
surgery. For patients whose tumors are un-resectable, the administration of chemotherapy 
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drugs has extended median overall survival by 5 months compared to patients who received 
only supportive care [8].  
Chemotherapeutic drugs used for the treatment of CRC include oxaliplatin (OXL), 5-
fluorouracil (5-FU), capecitabine and irinotican [8]. Due to the limited efficacy and the 
tendency of the tumor to acquire resistance for single use of drugs, most of these chemo agents 
are used in combination as various chemotherapy regimens [9]. Detailed description of each 
regimen is beyond the scope of this thesis. This chapter primarily concentrates on the 
description of OXL, as it is the only effective third-generation platinum drugs for advanced 
CRC and serves as the essential component of many combination chemotherapies regimens.  
1.2 Oxaliplatin  
The addition of oxaliplatin (OXL) has significantly improved the treatment outcome of 5-FU-
based therapy for metastatic colorectal cancer (mCRC), which had been used for decades in 
clinic with limited efficacy [10]. The role of OXL as an essential component of first-line or 
second-line treatment regimens for mCRC patients has been established in several landmark 
clinical trials due to its unique properties in its chemistry, biotransformation and mechanisms 
of action against colorectal cancer [11].   
1.2.1 Biotransformation 
OXL consists of an oxalate ligand as leaving group and the diaminocyclohexane (DACH) 
ligand (Fig. 1-1). The DACH ligand is chemically inert and the bi-dentate oxalate group is 
subject to attack by two H2O, Cl2 ions and HCO3, forming monochloro-, dichloro-, and 
Pt(dach)-(H2O)2 in biological fluids in vitro and in vivo. These reactions are non-enzymatic 
and considered as key steps to the activation of the pharmacological effect of OXL [12].   
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Figure 1-1. Chemical structure of oxaliplatin 
Oxaliplatin is composed of DACH and oxalate ligands. Adapted from [13]. 
Two of the biotransformation products of OXL, namely, (dach)(H2O)Cl and Pt(dach)-(H2O)2 
have been shown to be 2.9- and 3.7-fold more cytotoxic than the parental drug against colon 
cancer HT-29 cells. These two derivatives display higher cellular uptake compared to parental 
OXL. When colon cancer HT-29 cells are incubated with these two drug metabolites, 71-74% 
of Pt(dach)(H2O)Cl and Pt(dach)-(H2O)2 are detected in cytosol. In aqueous solution, OXL is 
about 40-fold less reactive than Pt (dach)Cl2 and more than 900-fold less reactive towards 
DNA than Pt(dach)(H2O)2 [14].  
Momofucntional species seem to be the predominant biotransformation products of OXL 
detected in in vitro and in vivo experiments. Using 3H-labeled OXL, more than 17 platinum 
complexes in plasma ultrafiltrate have been identified after a 24-h incubation, including 
methionine-bound platinum products (6%), monochloro (37%), monochlorocreatinine (9%), 
dichloro (10%), monocreatinine (4%) and other species [15]. Similarly, monochloro-DACH 
platin accounts for 31-100% of the biotransformation products identified in the plasma 
ultrafiltrate of cancer patients after a 2-h infusion with 130 mg/m2 OXL [16].  
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1.2.2 Mechanism of action 
OXL exerts its pharmacological effect through the formation of Pt-DNA adducts [17]. Upon 
entering cancer cells, OXL binds to the N (7) site of the guanine residues, forming transient 
mono-adducts and stable di-adducts. The biotransformation products of OXL then form 
approximately 60–65% intra-strand GG, 25-30% intra-strand AG, 5-10% intra-strand GNG, 
and only 1-3% inter-strand GG adducts with DNA double strands [18]. Intra-strand adducts 
cause the most severe DNA lesions, which further inhibit DNA replication and transcription 
[19] (Fig. 1-2), leading to activation of apoptotic pathway involving caspase 3 activation, 
translocation of apoptosis regulator BAX in the mitochondria, and release of cytochrome C in 
the cytosol [17].  
 
 
Figure 1-2. Oxaliplatin-DNA adducts 
G, A represent guanine and adenine bases, respectively. OXL binds covalently with G and A, 
forming intra-strand GG, intra-strand AG and inter-strand GG. Figure was adapted from [20]. 
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Although OXL and cisplatin form the same type of adducts at the same sites on DNA, the 
bulkier size of the DACH-Pt-DNA, and the constraint of the N–Pt–N bond angle can explain 
the superior cytotoxic effect over cisplatin. Moreover, these two features also prevent the 
mismatch repair proteins and some damage-recognition proteins from binding properly to 
OXL-GG adducts [21]. In addition, the cytotoxic effect of OXL on various malignancies is 
mediated through other less-defined pathways, including inhibition of DNA and messenger 
RNA synthesis as well as activation of immunologic death [22].  
1.2.3 Tumor resistance and platinum accumulation  
Despite improved efficacy and tolerability of OXL compared to other platinum drugs, the 5-
year survival rate of CRC patients after OXL treatment is only 12.5% [23]. Intrinsic resistance 
and acquired resistance are considered as the significant limitation for its use [24]. Therefore, 
understanding the mechanisms behind drug resistance is essential to developing targeted 
therapies to overcome this problem.  
The mechanisms of OXL resistance are not fully understood yet but it is generally thought to 
be a multiple factors including increased drug inactivation, improved drug-induced DNA 
damage repair, and evasion of apoptosis in tumor cells [25]. However, a reduced cellular 
accumulation of OXL has been frequently reported in unwanted drug-resistant human cancers 
including colorectal cancer, ovarian cancer, and squamous cancer. For instance, the cellular 
uptake of OXL and its DNA binding in OXL-resistant human colon cancer S1 cells is reported 
to be only 20% and 9% compared to the parental S1 cells, respectively. The uptake of OXL is 
inversely proportional to the IC50 for five S1 cell lines [26]. The accumulation of OXL in 
platinum resistant A2780-E (80) is only 3-38% of the parental A2780 cells over a broad drug 
concentration range [27]. The OXL-resistant human ovarian cancer 2008, A2780, IA-9 and 
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IGROV-1 cells and the squamous cancer UMSCC10b cell line exhibited an average of 27 ± 
10 % reduction of cellular OXL uptake compared to that of the matched sensitive cells [28].  
Cellular accumulation of drugs is dependent on the movement of drug in both directions, 
namely, an inward uptake process and an outward efflux process. Therefore, studying the 
determinants of these two transport processes is crucial to understanding drug accumulation 
and its relation to tumor resistance. This is particularly important to OXL, as high cellular OXL 
accumulation is correlated with increased platinum binding to its putative target, the nucleus 
DNA, and favorable antitumor activity [27].  
1.2.4 Cellular transport of OXL and membrane transporters 
For many years, it has been assumed that platinum drugs enter cells through passive diffusion, 
which is considered to be concentration-dependent and non-saturated [29,30]. However, it has 
become apparent that membrane transporters are likely to mediate the translocation of OXL 
across biological membrane. Membrane transporters that have been implicated in the cellular 
transport and tumor resistance to OXL, including organic cation transporters, multidrug and 
toxin extrusion protein and the human ATP-binding cassette proteins [31,32]. These 
transporters are thought to either control the influx of OXL as uptake transporters [33], or 
regulate the efflux of OXL as efflux transporters [34]. However, the association of copper 
transporters with cellular uptake of OXL is largely undefined yet compared to those above-
mentioned membrane transporters.  
1.3 Copper transporters  
Cu transporters belong to a group of important proteins that are responsible for the maintenance 
of copper homeostasis in mammalian cells. The main members include Cu uptake transporter 
1 (CTR1), efflux transporters Cu2+-transporting P-type ATPase ATP7A and ATP7B [35]. 
Current evidence has shown copper transporters are implicated in the transport of OXL despite 
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the lacking of direct evidence. In addition, the cellular localization and expression of these 
transporters undergo changes in the presence of Cu chelators, copper salts or platinum 
anticancer drugs. The mechanisms of these interactions are not clear yet but may become the 
molecular basis to enhance the cellular accumulation and the cytotoxicity of OXL in colorectal 
cancer cells.  
1.3.1 Contribution of Cu transporters to oxaliplatin transport in cancer cells: current 
evidence 
1.3.1.1 Copper uptake transporter 1 (CTR1) 
Human copper uptake transporter 1 (hCTR1) is a major Cu uptake transporter in cells. hCTR1 
is a 190-amino acid protein of ~28 kDa, with an extracellular N-terminal domain, three 
transmembrane domains and a C-terminal tail region containing about 15 amino acids (Fig. 1-
3A). hCTR1 is ubiquitously expressed in wide range of cell types, including hepatocytes, C 
cells of the thyroid and entero-endocrine cells [36]. The subcellular localizations of hCTR1 
are reported to be either plasma membrane or peri-nucleus, depending on the cell types and 
the copper status in the culture of these cells [37]. hCTR1 delivers copper into cytoplasm for 
the synthesis of cuprous enzymes such as cytochrome c oxidase and copper/zinc superoxide 
dismutase. These enzymes are crucial to the biological processes such as respiratory oxidation, 
neurotransmitter synthesis and pigmentation [38]. Structurally, it is reported that three 
monomers of hCTR1 unit form a stable homotrimer that is embedded in the plasma membrane 
like a channel [39]. Copper is supposed to pass through this channel through a serial 
transchelation reactions with methionines, histidines and cystenines in the stacked rings inside 
this channel [40] (Fig. 1-3B).  
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Figure 1-3. Molecular structure of hCTR1 
A. hCTR1 monomer is composed of an extracellular N terminus and cytoplasmic C terminus, 
and three transmembrane domains. B. Three monomers form a channel-shaped trimer through 
which copper is trans-chelated into the cell [41]. 
Unexpectedly, early studies show CTR1 may regulate the OXL uptake in some non-cancerous 
cellular models such as yeast, mouse embryonic, and HEK293 cells. A significant decrease in 
OXL accumulation is observed in BY4741-YPR124W yeast cells genetically deleted of CTR1 
gene compared to that of parental BY4741 strain when exposed to various concentrations of 
OXL for 1 h [42]. Loss of mouse CTR1 protein (mCTR1) in mouse embryonic fibroblast cells 
is associated with a substantial reduction of OXL accumulation by 63.7% compared to the 
CTR1+/+ cells when exposed to 2 μM drug for 1 h. This is accompanied with a 1.7 ± 0.6-fold 
difference in sensitivity to OXL between these two cell lines [43]. When exposed to 300 μM 
OXL for 5 min, mouse embryonic fibroblasts CTR1-/- cells that do not express CTR1 only 
accumulate 32% of the drug compared to that of wild-type CTR1+/+ cells [44]. Human 
embryonic kidney 293 cells (HEK293) that are transfected to stably express rat CTR1 
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(HEK/rCTR1) have shown about 4-fold higher OXL accumulation rate than in HEK293/mock 
cells (0.0004 vs 0.00012 nmol Pt/mg protein/min/mM). HEK/rCTR1 cells are 3-fold more 
sensitive than HEK293/mock cells to the cytotoxicity of OXL after 5 min drug exposure [45].  
hCTR1 is implicated in the uptake of OXL in gastric adenocarcinoma or small cell lung cancer 
(SCLC). The role of hCTR1 in OXL transport is investigated in a study using wild type and 
recombinant gastric adenocarcinoma S3 cells. The RT-PCR analysis shows that hCTR1 
mRNA level in resistant gastric adenocarcinoma S3 cells is about 20% lower than that in 
parental cells TSGH. When exposed to various concentrations of OXL for 4 h, the total 
platinum accumulation in S3 cells is only 12% of that in TSGH cells at the concentration of 
100 μM. The amount of OXL–DNA adducts in S3 cells are about 85% less than that in TSGH 
cells at the concentration of 100 mM OXL. The amount of OXL–DNA adducts in S3 cells are 
also about 85% less than those in TSGH cells at the concentration of 100 mM OXL. More 
DNA double-strand breaks are identified in TSGH cells than that of S3 cells following a 24-h 
exposure to various concentrations of OXL [46]. Decreased uptake of OXL is found in resistant 
SCLC cells that exhibit a 50% reduction in hCTR1 mRNA expression compared to the parental 
SCLC cells. Transfection of hCTR1 gene in SCLC cells increases the uptake OXL compared 
to the empty vector transfected Mock cells. In addition, the hCTR1 transfected cells become 
more sensitive to the cytotoxic effect of OXL  (IC50: 24.5  ± 3.5 vs 15.5  ± 5.9 μM) [47].  
Studies investigating the association of the expression copper transporters with OXL uptake 
and resistance in colorectal cancer (CRC) are limited. An early study demonstrated for the first 
time that reduced hCTR1 gene expression is related to OXL resistance in a colorectal cancer 
cell line. In this study, hCTR1 expression level is significantly reduced in OXL-resistant sub-
lines HTOXAR1, HTOXAR2 and HTOXAR3 by 65%, 63% and 46%, respectively as 
compared to that in parental cell line HT-29 [48]. Similarly, hCTR1 mRNA expression levels 
is demonstrated to be positively correlated with the accumulation of OXL in a panel of CRC 
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cell lines including Caco-2 DLD-1, HCT-15, HCT116, LS180, SW620 and WiDr cells using 
a Pearson’s correlation analysis [49]. The hCTR1 mRNA expression levels are highly related 
to the accumulation of OXL in CRC and ovarian cancer cells [50]. 
However, there are also some conflicting reports showing hCTR1 is unlikely to be the 
transporter of OXL. For instance, the uptake rate of OXL does not differ significantly between 
wild type mouse embryonic fibroblast cells and its subline without the expression hCTR1 [42]. 
The accumulation of OXL is found not hCTR1-dependent in CRC cells exposed to higher 
concentrations of OXL, suggesting the involvement of other mechanisms other than hCTR1 at 
this condition [51]. The hCTR1 expression levels in tumors of 39 CRC patients are not 
correlated with the treatment outcome for these patients following OXL-based chemotherapy 
in a recent small case control study [52]. 
1.3.1.2 Efflux transporters ATP7A and ATP7B 
Human Cu transporting P-type ATPase ATP7A protein, also known as Menkes’ 
protein, transports Cu outward across cell membrane using energy generated from ATP 
hydrolysis [53]. The protein structure consists of a cytosolic amino-terminus, eight 
transmembrane helices, an ATP-binding domain, an actuator domain and a cytosolic carboxyl-
terminus (Fig. 1-4) [54].  The N-terminus of human ATP7A contains six metal binding sites 
that are capable of binding to Cu. The eight transmembrane helices form a channel for copper 
translocation.  
In steady state, ATP7A is localized in the Golgi apparatus, where it is responsible for 
transporting Cu+ to copper-containing enzymes, such as lysyl oxidase, which is essential to 
maintaining the structure and function of connective tissue and the nervous system [55]. When 
extracellular copper levels are elevated, ATP7A traffics to the cellular membrane to excrete 
excessive Cu until a new copper equilibrium is reached [54]. ATP7A gene is expressed in all 
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tissues except the liver. The function of ATP7A is tissue specific. In the intestine, it regulates 
Cu+ absorption from food into blood circulation. In other tissues, it eliminates excess copper 
out of cells or delivers copper to Golgi apparatus for synthesis of important cuprous enzymes. 
[56]. Mutation of ATP7A gene severely blocks the transport of copper from lumen to portal 
circulation, causing severe copper deficient Menkes Disease. 
 
 
 
Figure 1-4. Putative structure of ATP7A in plasma membrane 
ATP7A is composed of eight trans-membrane segments, one N terminus, one C terminus on 
the cytoplasmic and an ATP-binding domain providing the energy for transport of copper.  
ATP7B is another Cu transporting P-type ATPase, also known as Wilson’s disease 
protein (WND), which is approximately 57% homologous to the amino acid sequence of 
ATP7A. Like ATP7A, it is composed of a cytosolic amino-terminus, eight transmembrane 
helices, an ATP-binding domain, an actuator domain and a cytosolic carboxyl-terminus (Fig 
1-4). ATP7B expression is more tissue specific than ATP7A with the highest expression in 
liver compared to ATP7A. ATP7B is predominantly localized in the trans-Golgi network of 
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hepatocytes, functioning to excrete excessive copper into the bile. In Wilson’s disease, 
mutation of ATP7B gene leads to severe copper toxicity in liver and kidney [57].  
Studies investigating the links between ATP7A or ATP7B and OXL resistance in colorectal 
cancer (CRC) are sparse, yet still suggest some correlation.  An early clinical study shows 
patients with high mRNA levels of ATP7B in colorectal cancer have a poor treatment outcome 
after OXL-based therapy, suggesting that elevation of ATP7B expression is associated with 
OXL resistance [58]. The expression of ATP7A is positively correlated with the IC50 values 
of OXL in 7 CRC cell lines. [59].  The OXL-resistant CRC HTOXAR1, HTOXAR2 and 
HTOXAR 3 cells exhibit markedly lower ATP7A and ATP7B gene levels compared to that of 
parent HT-29 cells [60]. Recently, it has been reported that 5-FU could suppress the expression 
of the ATP7B in colon cancer LS180 cell line, which results in the re-sensitization of these 
cells to OXL. This is partly because of diminished capacity of ATP7B for sequestrating OXL 
into the endoplasmic reticulum [45]. The ATP7A expression levels are about 3-fold higher in 
S3 cells compared to that of parental TSGH cells, though the ATP7B protein levels are similar 
between these two cell lines [61-63].  Taken together, all these studies suggest that copper 
efflux transporters ATP7A and ATP7B are more or less associated with OXL resistance in 
different cancer types, although the mechanisms involved remain unclear. 
However, there are some conflicting reports about the role of ATP7A and ATP7B in predicting 
treatment outcome of OXL, and their contribution to the OXL accumulation and cytotoxicity. 
While it has been reported that ATP7B expression level is inversely correlated with treatment 
of platinum drugs for various cancers [51], a recent small case control study does not show a 
correlation between the expression levels of ATP7B in tumor biopsies and the response to 
OXL in the CRC patients [64]. Contrary to expectation, the expression levels of ATP7A and 
ATP7B do not seem to be significantly altered in the resistant and sensitive small cell lung 
cancer cell lines [65]. The overexpression of ATP7A or ATP7B in MeMNK and MeWND 
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cells render these cells more sensitive to OXL, which is contradictory to other reports [66]. 
ATP7A-overexpressing ovarian cancer cells exhibit significantly higher accumulation of OXL 
compared to that of Me32a cells following exposure to 6 or 15 μM drug for 24 h [67]. Similarly, 
stable overexpression of ATP7A in human ovarian cancer A2780 cells reasonably causes a 
0.6-fold more resistance of these cells to OXL compared to the empty vector-transfected 
control. This is correlated with a 1.7-fold more OXL accumulation in ATP7A-overexpressing 
cells other than the expected impairment of drug accumulation [68].  
1.3.2 Effect of Cu chelators on the expression of hCTR1 
The expression of hCTR1 is consistently reported to be elevated in cells cultured in copper-
depleted conditions to meet the nutrition demand [69]. Therefore, Cu chelators can be utilized 
to enhance the cellular accumulation of platinum drugs in resistant cancer cells by increasing 
the expression of hCTR1, a possible uptake transporter of platinum drugs. 
Earlier, it has been demonstrated that transfection of glutathione, an endogenous Cu scavenger 
up regulates hCTR1 protein level and enhances the uptake and cytotoxicity of cisplatin in small 
cell lung cancer cells [70]. Pre-incubation with non-toxic level of tetrathiomalybedate (ATTM), 
a clinically used Cu chelator, is shown to increase the sensitivity of human cervical cancer 
SiHa and ovarian cancer cells A2780, SKOV3 and OVCA4 to the cytotoxic effect of cisplatin, 
whereas this synergistic effect is not observed in CTR1-knockout mouse embryonic fibroblasts, 
suggesting a dependence on CTR1 [71]. ATTM, trientine and D-penicillamine (D-P) enhance 
the uptake and cytotoxicity of platinum anticancer drugs in ovarian cancer 2008, IGROV1, 
OVCAR3 and SKOV-3, glioblastoma A172 and small cell lung cancer cells, which is 
accompanied by an increase of hCTR1 expression [72].  
Cu chelators have shown synergism with cisplatin in animal or human cancers in an in vivo 
context.  D-P has been shown to potentiate the anti-tumour activity of cisplatin in a mouse 
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small cell cancer model which has higher hCTR1 expression in tumours [70]. ATTM enhances 
the antitumor activity of cisplatin in the HPV16/E2 mice, a cervical cancer model. This is 
accompanied with a 2.7-fold increase of cisplatin-induced Pt-DNA adducts in the cancerous 
cervix and a 23% reduction of blood plasma copper level [73]. Trientine has been shown to 
reduce plasma copper level and re-sensitize ovarian cancer patients to carboplatin with clinical 
responses in 4/5 patients who had advanced diseases that are resistant to previous 
chemotherapy [74].  
1.3.3 Effect of Cu chelators on copper efflux transporters 
Cu chelators are generally not considered to be able to change the localization of Cu efflux 
transporters, however they are found to reduce the expression of ATP7A [74]. Therefore, Cu 
chelators can be utilized to enhance the accumulation of platinum drugs by reducing the 
expression of Cu efflux transporter ATP7A, a possible efflux transporter of platinum drugs. 
ATP7A is identified as a relevant factor for mediating the cisplatin resistance in human breast 
cancer cell lines in an RNAi library-screening assay. Cisplatin combined with ATTM down 
regulates the ATP7A expression in vitro and in vivo cancer models. The amount of cisplatin 
bound to nucleus DNA in cisplatin/ATTM treated cells is significantly increased compared to 
that of cisplatin resistant cells. Cisplatin/ATTM double treatment induces 20% decrease of 
total cell survival for human breast MB-MDA-231 cancer cell line compared to that of cells 
treated with cisplatin alone. The enhanced anti-cancer activity of this double therapy can be 
observed in MDA-MB-231 xenograft mice intraperitoneally injected with cisplatin at 6-mg/kg 
body weight [75].  
1.3.4 Cu induces degradation or internalization of hCTR1 
hCTR1 protein undergoes numerous biological events in wide range of cell lines that are 
exposed to excessive copper, including endocytosis, degradation and internalization [76]. 
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These alterations are assumed to result in functional inhibition of hCTR1 to cope with the toxic 
effect of copper [76].  
The hCTR1-copper interaction is firstly reported in both Chinese Hamster Ovary (CHO), and 
HEK293 cells [76]. hCTR1 localizes in plasma membrane of CHO cells cultured in basal 
medium. When exposed to elevated copper, it redistributes to the cytoplasm with an apparent 
punctate vesicular distribution throughout the cytoplasm. The endocytosis of hCTR1 is 
observed in HEK293 cells exposed to copper for 10 to 180 min. hCTR1 is degraded when the 
exposure is extended to 2 h.  Interestingly, endocytosis even happens when cells are exposed 
to basal medium for 5 min. The endocytosis is tested to be clathrin-dependent after using 
specific markers for endocytosis [77].   
The copper-induced endocytosis or degradation is a common occurrence in various cancer 
cells such as breast cancer PMC42-LA, ovarian cancer OVCAR3 and SCOV3 cells, human 
hepatic cancer HepG2 cells, and cervical cancer cells when exposed to both 2.5 μM and 20 
μM copper for 30 min [77].  The phenomena are also repeatedly reported in other non-
cancerous cell lines, including human epithelial kidney 293 cells, the Madin-Darby canine 
kidney epithelial cells, and CHO cell lines [78]. The conserved His-Cys-His residues are 
considered to be essential to the regulatory endocytosis of hCTR1 in response to elevated 
copper [79]. The model of endocytosis of CTR1 in mammalian cells has recently been 
proposed. According to this model, hCTR1 internalizes through clathrin or dynatin-mediated 
pathways. It translocates to the plasma membrane through Rab-11-dependent recycling 
pathway [80]. However, there are also conflicting reports regarding the response of hCTR1 to 
Cu. For example, it is found that CuO up regulates both the mRNA and protein levels of hCTR1 
in Caco-2 cells [81]. 
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Interestingly, such internalization and degradation of hCTR1 has also been reported following 
OXL addition to human cancers, probably through a proteasome-mediated pathway. Hence, 
compounds that can prevent the degradation of hCTR1 have the potential to enhance the 
cytotoxic effect of OXL, including bortezomib and some plant-derived anti-cancer compounds. 
The synergistic effect is firstly observed in combination study of OXL with bortezomib in the 
treatment of cisplatin-resistant ovarian cancer A2780, A2780cisR, A2780ZD0473R and 
SKOV-3 cells [82]. This is attributable to the role of bortezomib as proteosomal inhibitor to 
prevent the degradation of hCTR1 as documented in other studies.   
Chang-Wei-Qing (CWQ), a Chinese herbal formula, used clinically to treat cancers shows 
synergistic effect with OXL for the treatment of colorectal cancer partly by restoring the down 
regulation of hCTR1 caused by OXL. OXL triggers the degradation of hCTR1 gene and 
protein in colon tumour tissue grafted in nude mice. The combination of CWQ/OXL restores 
the hCTR1 expression in the tumour and enhances the antitumor effect of OXL by 53.6%. The 
survival time of nude mice bearing the tumours is significantly prolonged in CWQ/OXL group 
compared to that of OXL group [83]. 
 β-elemene, a compound extracted from the Chinese herb, Curcuma Wenyujin, has been 
approved by China’s State Food and Drug Administration. The immunohistochemical study 
shows the hCTR1 in tumour tissue of a mouse model is decreased after treatment with OXL. 
The levels of hCTR1 in OXL/β-elemene group are restored to that of control group. Consistent 
with these results, OXL plus β-elemene significantly enhance the anti-tumour activity in the 
mouse model implanted with human hepatoma MHCC97H cells, compared to that of OXL 
alone [84]. 
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1.3.5 Cu induces trafficking of ATP7A and ATP7B  
ATP7A and ATP7B transporting proteins are closely related to each other in both structure 
and function. These two proteins have both biosynthetic and protective roles in cellular copper 
homeostasis. Under normal conditions, both proteins are located in the trans-Golgi network 
(TGN) of the cell. They resurface to the plasma membrane or vesicles around the membrane 
when cellular copper is excessive, thus pump out copper to restore copper homeostasis [85].  
For instance, a 3-h incubation with 10 μM copper causes apparent trafficking of ATP7A from 
TGN to the cell periphery in B16F10 melanoma cells [86]. ATP7A shows predominant TGN 
localization in cervical cancer HeLa cells under steady-state conditions. When exposed to 200 
μM CuCl2 for 2 h, it moves to the cell surface [87]. Similar response modality is observed in 
human ovarian cancer 2008 cells, and human breast cancer PMC42 cells [80].  Similarly, 
copper also induces the redistribution of ATP7B from the TGN to a cytoplasmic vesicular 
compartment in hepatoma cells HepG2, human bladder carcinoma cells HBT9, and human 
cervical HeLa cells [88]. However, it is also possible that copper level can be rebalanced by 
changing the expression of ATP7A and ATP7B.  For example, CuO and CuSO4 increase the 
mRNA and protein levels of ATP7A in Caco-2 cells [89] in a concentration dependent way. 
Copper at 25 μM increases ATP7A mRNA level by 3.1 folds after 4 to 24-h exposure [90]. 
Copper at 200 μM for 16 h induces a significant 1.8-fold increase of its protein expression in 
rat intestinal epithelial (IEC-6) cells [91].  
Similarly, platinum drugs such as cisplatin seems to have similar effects on the localization of 
Cu efflux transporters, as copper does, to detoxify the toxic effect of these chemicals. Thus, 
blocking the trafficking machinery is a possible strategy to overcome the platinum drug 
resistance. Cisplatin at 5 μM for 1 h is able to change the localization of both ATP7A and 
ATP7B in A2780 cells from the perinucleus region to more peripherally located sites in the 
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cytosol. This is reversible 1 h after drug is removed from the culture medium. No effect is 
observed in resistant cell lines [92]. The effect of cisplatin on localization of ATP7B is 
evaluated in human ovarian carcinoma cells expressing a cyan fluorescent protein-tagged 
ATP7B (2008/ECFP-ATP7B). ECFP-ATP7B is localized in the perinucleus region in absence 
of drug exposure and that 2 μM cisplatin for 1 h causes the redistribution of this complex to 
more peripheral vesicles [93]. 
Proton pump inhibitors are clinically used drugs for the treatment of gastro-oesophageal reflux 
disease as they reduce gastric acid production from gastric parietal cells. They act by 
irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme in these cells 
[85].  A recent study shows PPIs have the potential to block ATP7A relocalization from the 
trans-Golgi network to the plasma membrane in response to elevated copper concentrations in 
melanocytes [94], therefore, this type of drugs have the potential to enhance the sensitivity of 
cisplatin in cancers as part of  a patent registration [95,96].   
1.3.6 Expression of hCTR1, ATP7A and ATP7B in colorectal cancer tissues 
While previous sections discuss the roles of copper transporters in the transport of platinum 
drugs, information about their expression in CRC is equally important, as knowing this is a 
guide for targeting copper transporters to increase the sensitivity of cancer cells to platinum 
drugs. Moreover, their expression status in tumour tissues is also likely to become a molecular 
marker to predict some treatment outcomes for OXL-based chemotherapies. Therefore, this 
section summarizes current literature about the expression of hCTR1, ATP7A and ATP7B in 
CRC tissues. 
1.3.6.1 hCTR1 
Copper is an essential micronutrient for normal cellular physiology. Since cancer cells have a 
significantly higher proliferative rate compared to normal cells, it is thought that they require 
 40 
more copper than normal cells. Copper also affects additional aspects of cancer growth, such 
as angiogenesis and metastasis [70]. Considering the roles of copper in the development of 
cancer, it can be expected that hCTR1 expression be up regulated in cancers to meet the 
metabolic and nutritional requirement for copper. Early studies seem to support this hypothesis. 
For example, significant elevation of mouse CTR1 protein (mCTR1) level is detected in the 
cervical tumor of the HPV16/E2 mice compared to the wild-type cervix [97]. The mRNA 
levels of mCTR1 in the pancreatic islets undergoing tumorigenesis are found to be elevated 
compared to that in the wild-type mice, and this phenomena is linked to copper-independent 
growth of tumors through oxidative phosphorylation [98].  
Although hCTR1 expression in human CRC has been investigated by several recent studies 
recently, the results are not consistent. hCTR1 mRNA levels are reported to be significantly 
up regulated in human CRC Caco-2, HT-29, and HCT-116 cell lines compared to that of the 
normal colon mucosa [99]. Its gene expression is also increased in 27 CRC tumour samples 
compared to that of 19 matched normal colonic tissue controls [100].  However, hCTR1 protein 
expression seems to be only related to the staging of cancer, since positive rates for hCTR1 
staining are measured as 0/45, 5/21, 0/21, 14/21 for colonic adenomas, adenocarcinoma T1 or 
T2, adenocarcinoma T3 or T4 and carcinoma metastatic to lymph nodes respectively. In 
contrast, hCTR1 are not detected in rectal carcinoma (0 out of 6 cases). Therefore, hCTR1 
seems to be reduced in CRC cancers (19 out of 108 cases) compared to positive rate of normal 
colon tissue (16 out of 42 cases) [101].  
hCTR1 protein expression is detected in 75 colorectal cancer patients with cytoplasmic 
staining pattern [51], which is replicated by a second study where hCTR1 exhibits moderate 
cytoplasmic staining in 31 colorectal cancer patients [102]. However, comparative information 
in relation to staining intensity of normal colon tissue samples is not provided in these studies, 
which makes the interpretation of those results questionable. 
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1.3.6.2 ATP7A and ATP7B 
Literature about the expression of the human copper efflux transporters ATP7A or ATP7B in 
CRC is limited, however the information about their expression in other cancers suggests they 
might be elevated in the development of CRC.  
ATP7A is expressed in 8 of 34 cases (23.5%) clinical colon cancer specimens but not in the 
adjacent normal epithelium [103]. ATP7A is more frequently detected in cancers including the 
prostate, breast, stomach, colon, lung, ovary, thyroid and pancreas than in normal tissues [104].  
In addition, ATP7A expression is present exclusively in 41.6% of non-small cell lung cancer 
patients but not in the normal tissues [105].  Overall, the current data show that ATP7A is more 
abundantly and differentially expressed in cancer tissues than their normal counterparts, 
suggesting its involvement in cancer development. 
Similarly, information about the expression of ATP7B in human CRC tissues is scarce and not 
conclusive. Recent study shows ATP7B is expressed in most colon cancer tissues (47 of 50 
cases) with various levels of expression intensity for both protein and mRNA [101]. In addition, 
ATP7B is detected in all 75 colon cancer specimens with nucleus-associated localization in 
comparison with the widely reported trans-Golgi network-related localization in other cells 
[106].  
However, ATP7B seems to be differentially expressed in many human cancers including 
ovarian cancer, oral cancer, gastric cancer, breast cancer and hepatic cancer. ATP7B gene is 
detected in 43.9% of ovarian carcinoma patients [63]. While ATP7B staining is negative in 
normal squamous epithelial cells, it is detected in 54.9% in human oral squamous carcinoma 
with cytoplasmic staining pattern [107]. Variable degrees of cytoplasmic staining of ATP7B 
are observed in 51.0% of gastric cardiac carcinomas tumor compared to 22.4% for the adjacent 
non-neoplastic epithelium [108].  Its expression is reported in 22% breast cancer samples, 
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while no staining is detected in the normal duct tissue [109]. Similar staining pattern is found 
in hepatic carcinoma with 21% positive staining rate compared to the negative staining in 
normal tissues [110].  
In summary, this section shows that copper transporters seem to be changed in the chronic 
process from normal tissues to cancer. To study the mechanisms for these alterations in 
carcinogenesis, it is necessary to look at the possible changes of copper, copper-containing 
enzymes in the pre-cancerous conditions such as chronic colitis or colonic dysplasia.  
1.4 Possible roles of copper in chronic colitis and colorectal cancer 
1.4.1 Pathological transformation from chronic colitis to colorectal cancer 
The development of CRC starts from an abnormal growth of tissue such as polyps and 
adenoma in the colon and rectum, which have the ability to transform into adenocarcinomas 
over a period of more than 10 years [111]. This malignant transformation can be accelerated 
by multiple factors including chronic inflammation, diet, environmental factors and family 
history [112]. Chronic inflammation of colon normally takes the form of ulcerative colitis (UC) 
and occasionally Crohn’s disease (CD). UC is a chronic, relapsing inflammation of colon and 
is consistently considered to be a well-established biological risk factor for the development 
and progression of colorectal cancer. Although inflammation-related CRC is estimated to be 
responsible for less than 2% of all CRC cases diagnosed annually, the mortality from colorectal 
cancer in the setting of UC is higher than that of sporadic colorectal cancer [113].  
Long-standing inflammation in colon causes colonic dysplasia, which is a transitional stage 
between UC and CRC, and therefore it is routinely examined as a surveillance marker for 
neoplasm in colon of patients with intestinal colitis [114]. Interestingly, the molecular 
alterations that are responsible for the development of CRC also have been detected in 
dysplastic tissues including the mutations of cyclooxygenase-2, p53, and adenomatous 
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polyposis coli [115]. Therefore, the development of CRC in the setting of inflammation seems 
to follow a stepwise colitis-dysplasia-carcinoma process, which has also been reported in lung 
cancer [116] and liver cancer [117].  
1.4.2 Copper homeostasis and chronic colitis  
Copper has been described to possess pro-inflammatory property [118].  Copper generates 
reactive oxygen species in the process of biochemical reactions, which triggers the release of 
pro-inflammatory cytokines such as interleukin 1 beta, tumor necrosis factor and 
cyclooxygenase 2 (COX-2) [119]. Moreover, components of copper homeostasis seem to be 
deregulated in inflammatory conditions of colon [120]. For a complete understanding of the 
biochemical role of copper in chronic inflammation of colon, it is essential to interrogate the 
role of copper transporters and copper-containing enzymes in inflammation.  
1.4.2.1 Copper levels  
Copper levels are found to be higher in inflamed tissues of colon from patients with UC and 
CD, although the exact role of copper in these diseases is still not clear yet. In a multicenter 
clinical study to monitor the serum copper levels in 47 patients with CD, 117 patients with UC, 
and 123 healthy controls, significantly high levels of serum copper are found in patients with 
these two disorders after adjusting for age, sex, and county of residence. This is the first large-
scale study to measure the relative copper levels in patients with intestinal inflammation 
compared to the healthy patients. The study links the excess of copper to be a factor for 
worsening the inflammatory process in UC and CD, as copper has the ability to catalyze free 
radical formation and increases the oxidative stress of the mucosa [121]. Similar finding is 
reported in a case-control study with 50 patients with UC, and 49 healthy volunteers. Mean 
serum copper level in patients with UC is 138.3 ± 42.6 μg/dl compared to 110.0 ± 38.5 μg/dl 
in the healthy individuals [122]. In children with CD, serum copper is also elevated compared 
 44 
to healthy controls (22.7 ± 5.49 vs 20.76 ± 4.06 mmol/L). However, in children with UC, 
copper levels are not changed [123].  
1.4.2.2 Copper containing enzymes  
Copper appears to have fundamental roles in inflammatory processes as described above. 
While the theory of free radicals can partially explain the elevated copper levels in 
inflammation [124], other factors such as copper-containing enzymes should not be ignored as 
they may be implicated in the development of inflammatory conditions of the colon, including 
lysyl oxidase, semicarbazide-sensitive amine oxidase (SSAO) and superoxide dismutase 
(SOD). A preclinical model shows that lysyl oxidase can suppress the secretion of monocyte 
chemoattractant protein-1 in cultured vascular smooth muscle cells, which inhibits the 
progression of inflammation [125]. In a recent study, gene profiling is conducted to identify 
any differentially expressed genes in the colon of rats with colitis induced by 2, 4, 6-
trinitrbenzene sulfonic acid administration. The gene of lysyl oxidase is found significantly 
increased in colonic tissues of the colitis model compared to the normal tissues, suggesting of 
a direct role in the pathology of UC [126]. 
Increased levels of SSAO have been associated with the development of UC. The pro-
inflammatory role of SSAO observed in these studies may be related to its ability to facilitate 
leukocyte tissue infiltration [127]. A subsequent animal study demonstrates that small 
molecule SSAO inhibitor LJP1207 could have a therapeutic effect against both acute and 
chronic inflammatory diseases. In the mouse model of UC, LJP 1207 significantly reduces 
mortality, and colonic cytokine levels as well as inflammation, injury and ulceration scores in 
mice [128].  
However, there are some cases where copper enzyme levels are decreased in UC. It is a known 
fact UC is induced in part from oxidative stress and SOD prevents the injury in the 
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gastrointestinal mucosa due to its free-radical scavenging role. In intestinal tissues from UC 
patients, the levels of Cu-SOD have been reported to be decreased which implies an adaptive 
response to inflammation [128].  
1.4.3 Contribution of copper to the development of colorectal cancer 
Cellular copper homeostasis is tightly regulated through the coordination between copper 
transporting proteins and copper chaperones. While the disruption of these components causes 
severe genetic diseases such as Wilson’s or Menkes’s diseases [129], they might be also altered 
in the development of malignancy in normal tissues. The observation that copper or copper-
containing enzymes rise in many cancers provides more evidence to support this speculation.  
1.4.3.1 Elevated copper levels in colorectal cancer tissues 
Early studies consistently show copper level appears to be increased in colorectal cancer (CRC) 
and other cancer tissues in comparison with the normal counterparts. Atomic absorption 
spectrometry demonstrates that the average copper level is increased by 46% in tumor tissues 
compared to normal tissues (2.08 ± 0.76 vs 1.42 ± 0.44 μg/g) [130]. Copper level is also higher 
in CRC than in normal tissues (1.9 vs 1.53 μg/g) [131]. In another study, mean copper level in 
CRC tissues is reported to be 170% to 180% of that in benign tissues derived from 25 patients 
[132]. Higher concentration of copper is also detected in CRC tissues from 30 patients 
compared to non-cancerous tissues (2.78 vs 1.79 μg/g) [95,96]. Similar findings are reported 
in breast cancer (21.0 ± 10.7 vs 9.3 ± 2.3 μg/g, dry weight) [133], and lung cancer (1.53 ± 0.35 
vs 1.17 ± 0.26 mg/g) [134]. 
The exact reason for the elevation of copper in CRC has not been fully understood yet. Copper 
is an essential micronutrient for sustaining the physiology of normal cells. CRC cells have 
higher proliferation rate therefore they require more copper than normal cells. Copper also has 
effect on multiple aspects of cancer growth, including angiogenesis and metastasis [135]. 
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Copper depletion has demonstrated efficacy against various types of cancers such as colon 
cancer, breast cancer, bladder cancer and ovarian cancer [136]. Copper may also act as a pro-
cancer factor in the development of cancer. Early studies show copper generates hydroxyl-
containing radicals that can bind to DNA and further break DNA strands leading to 
carcinogenesis [136]. Due to unknown defects, cancer tissue has stronger binding affinity for 
copper thus traps more copper as DNA-damaging element.  
1.4.3.2 Alteration of copper-containing enzymes in colorectal cancer tissues 
Copper ion is never free in cytoplasm of cells due to its high chemical reactivity. It exits as 
various copper-containing enzymes to fulfil the biochemical and metabolic functions required 
by cells [137]. In many cancers, especially CRC, the elevated copper level is also paralleled 
with enhanced expression of copper enzymes including lysyl oxidase (LOX), manganese 
superoxide dismutase (Mn-SOD), and cytochrome c oxidase (COX). These phenomena seem 
to be an interpretation for the elevation of copper in many cancers.  
LOX is a secreted copper-dependent amine oxidase whose primary function is to catalyse the 
covalent cross-linking of collagens and elastin in the extracellular matrix [138]. A recent study 
shows it is elevated in CRC tissue compared to the adjacent normal tissue and this up regulation 
is associated with the progression of CRC [139].  
Mn-SOD is a metalloenzyme that catalyses the dismutation of the superoxide anion to H2O2. 
Higher level of Mn-SOD level is frequently reported in colon cancer [140], human renal cell 
carcinomas [141], gastric adenocarcinoma and squamous cell oesophageal carcinoma [142] 
compared to the normal counterparts. Recent study shows the up regulation of Mn-SOD 
observed in these cancers facilitates the glycolysis of cancer cells [143]. 
COX is a large transmembrane protein complex present in the mitochondrion of mammalian 
cells. It is an important enzyme in the respiratory electron transport chain of mitochondria 
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[144]. One of its subunit COX IV protein and gene levels are reported to be significantly 
overexpressed in CRC tissue samples compared to the paired precancerous tissues [145]. 
While COX intensity progressively decreases in dysplastic epithelium, it is significantly 
increased in cancerous colon tissue [146]. However, cytochrome c oxidase subunit I shows 
decreased expression in crypts of CRC compared to that of the normal tissue (1.7 vs 22.8) 
[147].  
1.4.4 Animal models of chronic colitis and colorectal cancer 
Animal models have demonstrated to be important tools for testing potential therapeutic agents 
and for investigating the mechanisms of pathogenesis. It has been reported that there are 
currently more than 60 colitis models, which can be broadly classified into 5 categories, 
namely, the gene knockout, transgenic, chemical, adoptive transfer, and spontaneous colitis 
models [148]. Although these models are widely used to study many important aspects of the 
pathophysiological mechanisms and the effects of emerging therapeutic strategies, most of 
these experimental animals represent acute form of intestinal colitis, which is very rare in 
human.  
Winnie mouse has been developed as an animal model with Muc2 mutation to recapitulate the 
pathogenesis and clinical symptoms of chronic intestinal colitis. The Winnie mouse was 
originally established from the offspring of C57BL/6 mice carrying a single missense mutation 
in the Muc2 gene encoding the mucin protein produced by intestinal goblet cells, where the 
genetic mutation is induced by a mutagenic compound N-ethyl-N-nitrosourea. Muc2 mutation-
induced aberrant biosynthesis of mucin protein causes abnormal phenotypes similar to chronic 
colitis, such as impaired function of mucus barrier and increased susceptibility to luminal 
toxins in the intestine [148]. Phenotypically, Winnie mice display mild spontaneous distal 
intestinal inflammation at the age of six weeks with a 100% incidence, and 20% of the mice 
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develop severe clinical signs of chronic colitis by the age of one year. It has been assumed that 
the Muc2 mutation induces misfolding of the mucin protein, which triggers endoplasmic 
reticulum stress and activates of unfolded protein response in Winnie mice [149].  
Winnie mice are prone to colonic neoplasia due to the defective mucus barrier, chronic 
inflammation of colitis and continuous exposure to toxins in intestine. However, the rate of 
carcinogenesis is reported to be low in Winnie mice even at one year of age. Dextran sulphate 
sodium (DSS) is a commonly used chemical to cause colonic inflammation, dysplasia and 
carcinoma in mice. 
 DSS is reported to cause mutations of several genes that promote tumorigenesis in mice, such 
as Cav1, Ccl5, Myc, Trp53 [150]. After administration three cycles of 1% DSS for 21 days (7 
days/cycle) to Winnie mice, most of these animals display exacerbated colitis and sporadic 
dysplasia in the distal colon, which are considered to be relevant modeling of colorectal cancer 
arising from the context of chronic inflammation of colon [151].  
1.5 Rationale of study 
Oxaliplatin (OXL) is the backbone of many chemotherapy regimens for the treatment of 
advanced colorectal cancer. However, acquired resistance is a great barrier for its widespread 
long-term use. Efforts to prevent the resistance of OXL have thus far from been proven 
successful, and no effective strategy is available now to contain drug resistance. Reduced OXL 
accumulation is a predominant characteristic of many platinum-resistant cancers. Recently, 
membrane transporters mediating the trafficking of OXL have become a more acceptable 
theory. Therefore, targeting membrane transporters that control cellular OXL accumulation is 
a promising approach to circumvent drug resistance. Although several in vitro studies have 
shown that members of Cu transporters such as hCTR1, ATP7A or ATP7B may be also 
associated with cellular uptake and resistance of OXL, direct evidence is still lacking. The 
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information about the expression of copper transporters in colorectal cancer cell lines and 
determining their sensitivity to OXL are two necessary steps for selecting the appropriate 
models for following cell-based experiments. Understanding the expression of Cu transporters 
in colorectal cancer tissues relative to normal tissues is of great diagnostic and prognostic value. 
Moreover, elucidating their expression in the human colon specimens is helpful to translate 
the main findings from this project into a clinical context. Chronic colitis is a high-risk factor 
for the development of colorectal cancer. Copper and copper-containing enzymes are involved 
in the malignant transformation of colonic cells from a pro-inflammatory state to malignancy. 
Since copper transporters are key players in copper homeostasis, we hypothesized that the 
expression of Cu transporters may be changed in the sequential process that leads to cancer.  
1.6 Aims of thesis 
This project was undertaken with the hypothesis that hCTR1 determines the uptake and 
cytotoxicity of OXL in human colorectal cancer cells and it can be targeted with 
pharmacological compounds for the prevention of drug resistance. 
The specific aims of this thesis are: 
1) To determine the role of human copper transporter hCTR1 as an uptake transporter of 
OXL in colorectal cancer cells that stably overexpress the hCTR1 gene via recombinant 
plasmid-based transfection (Chapter 3).  
2) To investigate the therapeutic value of Cu chelators in enhancing OXL cytotoxicity in 
colorectal cancer cells by modulating hCTR1 expression (Chapter 4).  
3) To systematically investigate endogenous expression of the Cu uptake transporter 
hCTR1 and the efflux transporters ATP7A and ATP7B in tumor biopsy tissues of 
colorectal cancer patients (Chapter 5). 
4) To determine the role of copper transporters in the development of colorectal cancer 
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by studying their expression in colonic tissues of Winnie mice with colitis, DSS-treated 
Winnie mice with dysplasia and wild-type C57B/6 mice as normal control (Chapter 6). 
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Chapter 2 Materials and Methods 
2.1 Chemicals and reagents 
Oxaliplatin, cisplatin, copper chloride, D-penicillamine, ammonium tetrathiomolybdate and 
bathocuproinedisulfonic acid disodium salt were obtained from Sigma-Aldrich (St Louis, MO, 
USA). SuperScrip III First-strand synthesis system (50) and the selective antibiotic geneticin 
(G418) were purchased from Life Tech (Carlsbad, CA, USA). The Lipofectamine LTX with 
Plus reagent was from Thermo Fisher Scientific (Walttham, MA, USA). The C-terminal Myc- 
and DDK-tagged pCMV6-Entry vector was purchased from Origene (Rockville, MD, US). 
The Amersham ECL Western blotting detection reagent was obtained from Lumigen (Lumigen, 
MI, US). DAB enhanced liquid substrate system was bought from Sigma-Aldrich. FDCPt1 
was kindly provided by Dr Elizabeth New at the School of Medical Sciences, University of 
Sydney. All other reagents were from reputable suppliers, otherwise indicated.  
2.2 Cell culture 
Human colorectal cancer cell lines, DLD-1, SW620, HCT-15 and COLO205 were purchased 
from American Type Culture Collection (Manassas, VA, USA). All cells were maintained in 
Dulbecco's modified eagle medium (DMEM) (Sigma-Aldrich), supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA), at 37 °C in a humid 
atmosphere of 5% CO2-95% air. The human copper uptake transporter 1 gene- DLD-1/ hCTR1 
cells and the empty vector-transfected cells were maintained in fully supplemented DMEM 
medium containing 150 mg/mL G418. Cells were only used for experiments up to 20 passages 
and regularly tested for mycoplasma contamination.  
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2.3 Establishment of overexpressing DLD-1/hCTR1 colorectal cancer cells 
2.3.1 pCMV6 vector 
A pCMV6 expression vector containing the open reading frame (ORF) of human copper 
uptake transporter hCTR1 gene was constructed commercially by Origene (Fig 2-1). This 
vector is composed of bacteriophage f1 origin of replication (f1 ori), simian virus 40 origin of 
replication (SV40 ori), ColE1 origin of replication, a cytomegalovirus promoter (CMV), 
bacteriophage T7 promoter, and a multiple cloning site (MCS). The CMV and T7 promoters 
drive constitutive expression of hCTR1 protein in mammalian cells and bacteria, respectively. 
SV40 ori allows replication in mammalian cells. The MCS provides restriction sites for 
subcloning of the gene of interest.  The hCTR1 gene is tagged with the Myc and DDK genes 
for identification and isolation of the protein complexes. In addition, the Kan/Neo resistance 
genes in this construct allow positive selection in bacterial and mammalian cells, respectively. 
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Figure 2-1. The structure of pCMV6-Entry vector containing the ORF of human hCTR1 
gene 
The location of hCTR1 gene in this construct is indicated with red arrows. In this vector, a 
TrueORF sequence is fused with a Myc/DDK tag at its carboxy terminus. The image was 
modified from the manufacturer’s product information [152].  
2.3.2 Transfection  
Human colorectal cancer DLD-1 cells were stably transfected with pCMV6-Entry vector as 
indicated in section 2.3.1 or the corresponding empty vector to establish a mock control line 
according to the method previously developed in Dr Johnson Liu’s lab [44]. Briefly, DLD-1 
cells were seeded at a density of 400,000 cells/well of 6-well plates in fully supplemented 
DMEM growth medium and cultured overnight. On the next day, the transfection mixtures 
containing 10 μg purified DNA and Lipofectamine reagent were prepared and added into the 
cells in the 6-well plate according to the manufacturer’s instructions. After culture for 48 h, 
cells were split at a 1:5 ratio into a 100 mm-petri dish containing DMEM added with 1200 
μg/ml G418. The transfected cells were further cultured for extended period to allow the 
formation of colonies. After approximately two weeks, single colonies were isolated under a 
light microscope and screened for protein expression of hCTR1 using a Western blotting assay. 
The colony with the highest or lowest levels of hCTR1 was selected and further amplified 
through several passages to produce cell aliquots for long-term storage in liquid nitrogen. For 
maintenance, transfected cells were cultured in fully supplemented DMEM containing 150 
μg/ml G418 for subsequent experiments. The Gene Technology Research Committee at the 
University of New South Wales approved the use of transfected cell lines as Genetically 
Modified Committee (See Appendix C).  
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Cells were seeded into a 6-well plate in triplicate and left overnight to adhere. Cells were 
exposed to 200, 400 and 800 µM CuCl2 for 24 h or 1, 3 and 5 μM OXL for 2 h, and then 
cultured in drug-free media for about two weeks to allow colony formation. Cells were treated 
in parallel with drug vehicle as control. 
2.4 MTT assay and colony forming assay 
2.4.1 MTT assay 
The cytotoxicity of oxaliplatin (OXL) and CuCl2 was evaluated using an MTT-based assay. 
Colorectal cancer DLD-1, SW620, HCT-15 and SW620 cells were seeded at a density of 6000-
8000 cells/well into 96-well plates in fully supplemented DMEM growth medium and left to 
attach to the plates overnight. On the next day, cells were incubated with serial dilutions of 
0.01-500 μM OXL or CuCl2 solutions in serum-reduced Opti-MEM medium (Thermo Fisher 
Scientific) and cultured for either 2 h or 72 h under different incubation conditions as described 
above. Subsequently, 20 μl of 5 mg/L MTT solution in PBS was added to each well for 1 h 
before the medium was discarded and replaced with 200 μl DMSO (Sigma-Aldrich). The plates 
were shaken gently for 15 min at room temperature before absorbance (A570) was determined 
using a microplate reader (Spectra max, Bio-Strategy). The 50% growth inhibitory drug 
concentrations and the relative viability of cells were calculated using GraphPad Prism 
programs (GraphPad Software, Santiago, USA). 
2.4.2 Colony forming assay 
The colony forming assay (CFA) was performed to measure the inhibitory effect of OXL and 
CuCl2 on the colony forming capacity of hCTR1-overexpressing DLD-1/hCTR1 cells and 
mock control cells. Cells were seeded at a seeding density of 600 cells/well in 6-well plates 
and cultured in fully supplemented DMEM medium overnight. On the next day, cells were 
exposed to either CuCl2 or OXL under the experimental incubations described in section 3.4.2. 
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Cells were then maintained in drug-free culture for about two weeks while the media was only 
changed once during this period. At the end of the culture, cells were washed with 2 ml PBS 
for 1 min before 2 ml of 0.5% crystal violet solution (0.5% w/v crystal violet, 25% v/v 
methanol in PBS) was added to each well of the plate. Colonies were stained for 10 min at 
room temperature, followed by 2 washes with PBS to remove the excess dye. The blue-stained 
colonies containing more than 50 cells each were counted manually under a stereomicroscope 
and documented photographically. Images were processed using the Image J program 
(National Institute of Health, USA).  
2.5 Western blotting assay  
Human colorectal cancer cell lines, DLD-1, SW620, HCT-15 and COLO205 or DLD-
1/hCTR1 or the mock transfected cells were cultured with in fully supplemented DMEM 
medium for 2 to 3 days until confluence reached at least 80%. Cells were incubated with 
different concentrations of copper chelators, CuCl2, OXL or drug vehicle as control as 
described in Section 4.2. Following the treatments, cells were dissolved in ice-cold CelLytic 
lysis solution (Sigma) and centrifuged at 8000 ×g at 4°C for 15 min.  The protein concentration 
of the resulting supernatant was measured using a NanoDrop 2000 spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA). Protein samples (30 μg/lane) were heated at 90°C for 5 min, 
electrophoresed in 8% or 12% SDS-PAGE and then transferred to a PVDF membrane 
(Amersham, Buckinghamshire, UK) using a Transblot SD device (Bio-Rad, Hercules, CA). 
Following the blocking with 3% skimmed milk/bovine serum albumin in 0.2% Tween 20 
(TBST) solution, the blot was incubated with the primary antibody anti-hCTR1 (1:1000 Novus 
Biologicals, Littleton, CO; Cat. No: NB100-402), anti-ATP7A (1:1000 Abcam, Cambridge, 
UK; Cat. No: ab131400), anti-ATP7B (1:2000 Abcam; Cat. No: ab135571) or anti-β-actin 
(1:5000 Abcam; Cat. No: ab8226), horseradish peroxidase (HRP)-conjugated anti-rabbit 
(1:500 Abcam; Cat. No: ab97051) or anti-mouse secondary antibody (1:500 Abcam; Cat. No: 
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ab97023), and the ECL Advance Detection reagent (Lumigen). The density of resolved 
electrophoretic bands was quantified using Image J program and expressed as a ratio to that of 
β-actin.  
2.6 Reverse transcription polymerase chain reaction (RT-PCR) 
Total RNA was extracted from colorectal cancer DLD-1, SW620, HCT-15 and COLO205 cells 
using an EZ-10 DNAway RNA kit following manufacturer’s instruction (Bio Basic, Ontario, 
Canada). 0.25-0.5 µg RNA of each sample was reverse-transcribed into cDNA using a 
SuperScript III first-strand synthesis system and a thermal cycler (Bio-Rad). The cDNA 
synthesis reaction was conducted in 20 μl of reaction buffer at 42 °C for 50 min and was 
terminated by heating the mixture at 70 °C for 15 min. 5 µg cDNA of each sample was used 
to PCR amplify copper transporters and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
using platinum PCR SuperMix. cDNA was amplified by PCR in a reaction mixture containing 
dNTP, MgCl2, platinum Taq DNA polymerase and custom primers indicated in Tab 2-1 
(Geneworks, Thebarton, SA, Australia), using a C1000 thermal cycler (Bio-Rad). PCR was 
carried out with 35 cycles of 15 s at 94 °C, 30 s at 55 °C and 30 s at 72 °C. PCR products were 
electrophoresed on 1.5% agarose gel, stained with SYBR Safe DNA Gel Stain (Thermo Fisher 
Scientific, Waltham, MA), and photographed using Molecular Imager Gel Doc XR System 
(Bio-Rad). Gel images were further analyzed using Image J software. 
Table 2-1.  Sense and anti-sense primers for copper transporter or GAPDH genes 
Gene Primer sequence Size 
(bp) 
hCTR1 F 5’-AAGATAGCCCGAGAGAGCCT-3’ 
R 5’-AATCGATAAGGCCACGCCAT-3’ 
346 
ATP7A F 5’-TGGTGAAGTCGTGCTGAAGAT-3’ 
R 5’-TCATTGGTATGATGGACTCCTTTG-3’ 
322 
ATP7B F 5’-GAGGGCTATCGAGGCACTTC-3’ 
R 5’-GAGCCACTTCCTGCACAGAT-3’ 
446 
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GAPDH F 5’-TTCTTTTGCGTCGCCAGCC-3’ 
R 5’-CATGGTTCACACCCATGACGA-3’ 
455 
 
2.7 Fluorescent immunocytochemistry   
Human colorectal cancer cell lines, DLD-1, SW620, HCT-15 and COLO205 or DLD-
1/hCTR1 or the mock transfected cells were cultured in fully supplemented DMEM medium 
in 24-well plates for 2 to 3 days until the confluence reached 60-80%. Cells were incubated 
with different concentrations of copper chelators, copper chloride, oxaliplatin or drug vehicle 
as control as described in Section 4.2. After the incubation, cells were rinsed with cold PBS, 
followed by fixation with 4% formaldehyde in PBS for 15 min at room temperature, before 
being permeabilized with or without 0.2/% Triton X-100/PBS for 15 min. After 
permeabilization, Image-iT FX signal enhancer (Life Tech) was added to the cells according 
to the manufacturer’s instructions and incubated for 30 min at room temperature under humid 
conditions. Cells were then incubated with blocking buffer (PBS containing 0.2% Triton X-
100, 3% goat serum and 2% bovine serum albumin) for 1 h at room temperature before being 
exposed to the primary antibodies, polyclonal rabbit anti-hCTR1 (1:500 Novus), mouse anti-
ATP7A (1:500 Abcam), rabbit anti-ATP7B (1:50 Abcam) or mouse anti-Na+/K+ ATPase 
(1:1000 Abcam; Cat.No: ab58475) diluted in immuno-buffer (3% goat serum in PBS) 
overnight at 4ºC, followed by incubation with secondary antibodies, Alexa Fluor 488-labelled 
anti-rabbit IgG (1:1000; Life Tech: A11034) or Alexa Fluor 594- labelled anti-mouse IgG 
(1:1000) (Life Technologies, Carlsbad, CA; Life Tech: A11032) diluted in immunobuffer for 
3 h at 4 °C, protected from light. At the end of incubation, cells were rinsed and cover-slipped 
with Vectashield mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories, Burlingame, CA). Images were captured using a Leica fluorescence microscope 
(Leica Biosystems, VIC, AU) or confocal microscope (Nikon Instruments, Melville, USA) and 
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analyzed using NIS-ELEMENTS D 3.2 (Nikon, Tokyo, Japan) and Image J software (National 
Institute of Health, Bethesda, MD). 
2.8 Processing of tumor samples  
2.8.1 Collection of human tissues 
Tumor and the adjacent normal tissues collected from the bowel of colorectal cancer patients 
were identified by pathologists at the Royal Hobart Hospital. In total, 3 tumor samples and 3 
normal tissue samples from each patient were taken and rinsed with cold PBS before they were 
placed in cryovials and snap-frozen in liquid nitrogen. Tissues were then stored at -80ºC until 
use.  
2.8.2 Tissue embedding 
Frozen colon samples were fixed in pre-chilled PBS containing 4% 
paraformaldehyde overnight at room temperature, followed by dehydration in serial ethanol 
solutions (70-100%), clearing with xylene, and perfusion with paraffin before being embedded 
into tissue blocks by pathologists at the UNSW. Some non-fixed snap-frozen samples were 
also immersed in 30% sucrose in PBS solution at 4ºC overnight until the tissue sank, followed 
by embedding in Tissue-Tek optimal cutting temperature embedding compound (Sakura 
Finetek, Torrance, CA, USA), snap frozen in liquid nitrogen, and stored at -80ºC until used for 
cryosection.   
2.8.3 Sectioning of human tissues 
Paraffin or OCT-embedded tissues were sectioned following instructions. Briefly, paraffin 
blocks were placed on ice for at least 5 min before being cut into 4 μm-thick sections with a 
microtome (Leica Biosystems) at room temperature. Paraffin ribbons were placed in a water 
bath at about 40-45 ºC and mounted onto tissue slides coated with poly-lysine. Next, sections 
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were subject to air-drying for 30 min before being baked at 45-50 ºC overnight. OCT-
embedded frozen tissues were sectioned using a cryostat (Leica Biosystems) at −20 °C at a 
thickness of 4 μm before being mounted on poly-lysine coated slides, and stored at −80°C.  
2.8.4 Haematoxylin and eosin staining (H&E staining) 
H&E staining was performed according to established in-house protocols. Briefly, paraffin-
embedded mouse tissue slides were de-waxed by immersion in xylene (2×5 min), absolute 
ethanol (2×2 min), 70% ethanol (1×1 min) and 1 min under running tap water. Frozen sections 
were excluded from this step and directly warmed up for 1 min at room temperature. Slides 
were then dipped into haematoxylin solution for 4 min, followed by a 1-min wash under 
running water. Slides were differentiated in 1% acetic acid in ethanol for 30 secs before being 
washed under running tap water for 1 min. Slides were developed in 0.2 % ammonia water for 
30 secs to 1 min and counterstained using eosin solution for 3 min. Subsequently, slides were 
dehydrated in absolute alcohol (2×2 min), xylene (2×3 min) before excess xylene was drained 
off and the sections were mounted using a DPX mounting medium and analyzed by light 
microscopy. 
2.9 DAB-based immunohistochemistry 
DAB-based immunohistochemistry (IHC) was performed on paraffin-embedded or cryo-
sectioned tissues as previously reported [153]. Antigen retrieval of the tissue sections was 
conducted by microwaving the tissue slides at 105 oC for 15 min in pH 6.0 citrate buffer 
containing 10 mM sodium citrate and 0.05 % Tween 20 in distilled water. Tissue sections were 
then immersed in 0.3 % hydrogen peroxide (Sigma-Aldrich) in blocking buffer to inhibit 
endogenous peroxidases and block the nonspecific protein. Slides were then incubated with 
the primary antibodies, polyclonal rabbit anti-hCTR1 (Novus 1:250), mouse anti-ATP7A 
(Abcam 1:2000), or rabbit anti-ATP7B (Abcam 1:300) in immuno-buffer overnight at 4 ºC in 
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a humid condition. Negative controls were just incubated with immuno-buffer. On the next 
day, slides were then washed 3x 5 min with TBST and incubated with biotinylated secondary 
rabbit or mouse antibodies (Sigma-Aldrich) in immuno-buffer (1:500) for 2 h, followed by 
three washes with TBST. Slides were then incubated with a 1:500 dilution of HRP-conjugated 
extrAvidin (Sigma-Aldrich) for 1 h, and 30-50 µl DAB-substrate per tissue section for 30 secs, 
counterstained for 10 secs with haematoxylin and rinsed using running tap water for 1 min. 
Lastly, coverslips were mounted onto sections using DPX mounting medium (Sigma-Aldrich) 
and were air dried at room temperature before microscopic analysis.  
2.10 Statistical analysis 
All data are presented as mean ± standard deviation or as percent change compared to the 
untreated control. Statistical analyses were performed using GraphPad Prism (GraphPad 
Software Inc, CA, USA). Statistical significance of the data was evaluated using Student’s t-
test or paired t-test, and one-way analysis of variance (ANOVA), where appropriate, followed 
by Dunnett’s multiple comparison tests to evaluate the difference between different groups and 
control. A P-value of < 0.05 was considered statistically significant. IC50 values were 
calculated  using a nonlinear regression curve fit with 4 parameters.  
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Chapter 3 Recombinant Overexpression of hCTR1 
Enhances Oxaliplatin Cytotoxicity and Uptake in Human 
Colorectal Cancer Cells 
3.1 Introduction 
The goal of this chapter was to determine the role of human copper transporter 1 (hCTR1) in 
the transport of oxaliplatin (OXL) in colorectal cancer cells that were engineered to 
overexpress the transporter gene. The DLD-1 cell line is derived from the epithelial tissue of 
Duke’s type C human colon adenocarcinoma from an adult Caucasian patient [156]. The 
DLD-1 cell line carries genetic mutations of TP53, KRAS, PIK3CA, BRAF and PTEN, which 
are caused by chromosomal instability, microsatellite instability, and CpG island methylator 
phenotype pathways [157]. These genetic mutations and phenotypes are common in colorectal 
cancer, therefore, the use of DLD-1 line in this project aims to provide clinical relevance to 
the results. Herein, DLD-1 cells were transfected to stably overexpress hCTR1 as a valid cell 
model system (DLD-1/hCTR1) to study Cu transporter. In addition, DLD-1 cells were 
transfected with the corresponding empty vector to establish a mock control line. Western 
blotting assay was performed to detect elevated protein levels of hCTR1 in DLD-1/hCTR1 
cells in comparison to mock control cells. The function of hCTR1 in DLD-1/hCTR1 cells was 
verified based on enhanced sensitivity to copper chloride, the prototype substrate of hCTR1. 
OXL cytotoxicity and uptake were further measured in DLD-1/hCTR1 cells in comparison 
with that of mock control cells.  
Enhanced OXL accumulation in DLD-1/hCTR1 would be evident if hCTR1 contributes to its 
cellular uptake. Several biotransformation products of OXL are known to be responsible for 
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its pharmacological activity through the formation of Pt-DNA adducts, interfering with DNA 
replication and transcription, and leading to cancer cell death [158]. The hydrolysis products, 
including monofunctional monoaquatic Pt species, are more potent than the parent platinum 
drugs [159].  FDCPt1 is a fluorescein-based compound bearing a dithiocarbamic acid moiety. 
FDCPt1 exhibits a major absorption peak at 516 nm and an emission maximum at 540 nm. 
FDCPt1 could bind specifically with monofunctional metabolites of Pt drugs through Pi-Pi 
non-covalent interactions, which cause an increase of fluorescence emission by ~70 folds. 
This property has been used to detect the monofunctional metabolites of OXL, cisplatin and 
carboplatin in colorectal cancer cells [160]. Herein, we have utilized FDCPt1 as a specific 
fluorescent probe to monitor cellular accumulation of OXL-derived monofunctional 
biotransformation products in hCTR1-overexpressing DLD-1/hCTR1 cells and mock control 
cells for comparison.  
3.2 Experimental design 
3.2.1 Establishment of overexpressing DLD-1/hCTR1 colorectal cancer cells 
Human colorectal cancer DLD-1 cells were stably transfected with pCMV6-Entry vector as 
indicated in section 2.3.1 or the corresponding empty vector to establish a mock control line. 
Briefly, DLD-1 cells were seeded at a density of 400,000 cells/well of 6-well plates in fully 
supplemented DMEM growth medium and cultured overnight. On the next day, the 
transfection mixtures containing 10 μg purified DNA and Lipofectamine reagent were 
prepared and added into the cells in the 6-well plate according to the manufacturer’s 
instructions. After culture for 48 h, cells were split at a 1:5 ratio into a 100 mm-petri dish 
containing DMEM containing 1200 μg/ml G418 for selection. The transfected cells were 
further cultured for extended period to allow the formation of colonies. After approximately 
two weeks, single colonies were isolated under a light microscope and screened for protein 
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expression of hCTR1 using Western blotting. The colonies with the highest and lowest levels 
of hCTR1 were selected and further amplified through several passages to produce cell aliquots 
for long-term storage in liquid nitrogen. For maintenance, transfected cells were cultured in 
fully supplemented DMEM containing 150 μg/ml G418 for all subsequent experiments. The 
Gene Technology Research Committee at the University of New South Wales approved the 
use of transfected cell lines (See Appendix C).  
 
3.2.2 Sensitivity of transfected cells to oxaliplatin and CuCl2 (MTT and colony forming 
assay) 
Following the stable transfection and overexpression of hCTR1, the sensitivity of DLD-
1/hCTR1 cells to Cu chloride, a prototypic substrate of hCTR1, was further tested in 
comparison to the mock cells using the MTT and colony forming assays (CFA). These cell 
viability assays are designed to measure the metabolic activity and colony-forming ability of 
cancer cells. The MTT assay is a colorimetric assay for measuring the capacity of NAD (P) H-
dependent cellular oxidoreductase enzymes to reduce yellow 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) to purple colored formazan. The MTT assay is 
commonly used method to measure the cytotoxicity of anticancer drugs, since only viable cells 
are metabolically active and are able to convert the dye [157]. In addition, the CFA measures 
the clonogenic potential of cells and is commonly used as a surrogate method to evaluate long-
term cytotoxicity of anticancer drugs on cultured cells [161]. Therefore, the short and long-
term cytotoxicity of Cu chloride and OXL were fully evaluated in DLD-1 cells and mock cells 
using both the MTT and CFA assays. 
Briefly, DLD-1/hCTR1 or mock control cells were seeded into 96-well plate at a density of 
6000 cells/well in quadruplicate and cultured overnight. Cells were incubated with 5, 10, 30, 
50, 100, 300, 500 and 1000 μM CuCl2 for 72 h or 0.3-300 μM OXL for 2 h, and then cultured 
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in drug-free media for 72 h, followed by the conduction of the MTT assay. For CFA, DLD-
1/hCTR1 cells or mock cells were seeded at 600 cells/well into a 6-well plate in triplicate and 
left overnight to adhere. Cells were exposed to 200, 400 and 800 µM CuCl2 for 24 h or 1, 3, 5, 
10, 30 μM OXL for 2 h, and then cultured in drug-free media for about two weeks to allow 
colony formation. Cells were treated in parallel with drug vehicle as control. The selection of 
concentration range for each type of assay was based mostly on our preliminary results 
(unpublished data).  The drug concentration ranges to be used in the MTT assays were intended 
to achieve a minimum and maximal killing effect for each particular chemical under the 
corresponding experimental conditions. In a preliminary copper MTT assay, a range of 0.3-
500 μM for both DLD-1/hCTR1 or mock control cells achieved an approximate reduction of 
cell viability between 5% and 90% (data not presented). Therefore, to achieve a maximal 
killing effect, the dose range was adjusted to 0.3-1000 μM in the formal test. Likewise, using 
0-300 μM of OXL in the MTT assay was also intended to achieve a minimum and maximal 
killing effect. In addition, the OXL concentration range for MTT assay (0-300 μM) or CFA 
assay (1-30 μM) was selected to simulate typical blood plasma concentrations of OXL in 
cancer patients (14.6 ± 3.1 μM) [64]. However, since no viable cells were found following 
exposure to 100 and 300 μM of in the MTT assay, only the results for the 0-50 μM dose range 
were reported. Likewise, since OXL at 10 and 30 μM almost yielded a complete loss of 
colonies in CFA assay, only the data for the 1-5 μM dose range was presented in the figure. 
3.2.3 Detection of platinum anticancer drugs using a fluorescent probe FDCPt1 
The fluorescence probe FDCPt1 has been recently reported to detect platinum drugs in 
colorectal cancer cells, including oxaliplatin (OXL), cisplatin and carboplatin [161]. This 
probe provided an opportunity for us to examine the role of hCTR1 in the uptake transport of 
OXL in colorectal cancer cells since hCTR1 overexpression would be expected to enhance 
cellular uptake of OXL, if it plays a positive role in this regard. Briefly, hCTR1-overexpressing 
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DLD-1/hCTR1 cells and empty vector-transfected mock control cells were seeded at a density 
of 8x104 cells/well onto a sterile coverslip mounted on a 24-well plate. Cells were cultured 
under standard conditions for 2 days until the cellular confluence reached at least 50%. Cells 
were then exposed to 30 µM OXL for 2 h, respectively. Subsequently, cells were washed once 
with 2 ml pre-warmed PBS followed by the addition of 100 µM FDCPt1 prepared in warm 
PBS. After light protected incubation under standard culture conditions for 30 min, cells were 
washed once with 2 ml PBS and fixed with cold methanol for 15 min. After fixation, cells were 
washed three times with 2 ml PBS. The coverslip with fixated cells was removed from the well 
and mounted onto a microscopic slide, using Vector mounting media (Vector Laboratories, 
Burlinggame, CA, USA). Fluorescence images were captured using an upright fluorescence 
microscope (Olympus, Melville, NY, USA) at a wavelength of 488 nm for FDCPt1 signal, and 
358 nm for nucleus, respectively. The concentrations and incubation times for FDCPt1 were 
selected based on the recommended experimental conditions used in a recent study [160]. In 
addition, 30 µM OXL was the optimal concentration based on the results of my previous pilot 
study(unpublished data). 
3.3 Results 
3.3.1 Establishment of hCTR1-overexpressing colorectal cancer cell line 
In total, four G418-resistant colonies comprising of approximately 50-100 cells each were 
selected and subcultured in medium containing 150 μg/ml G418 as hCTR1-overexpressing 
clones. In parallel, two empty vector transfected clones were established in the same way of 
culture as mock control clones. 
The hCTR1 protein level of these hCTR1-overexpressing clones and empty vector-transfected 
mock control clones was measured using Western blotting analysis. In general, the level of 
hCTR1 protein was higher in hCTR1-overexpressing clones than those mock control clones. 
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Based on the densitometry analysis, the hCTR1 protein level appeared to be the highest in the 
clone 2 among all hCTR1-transfected clones, whereas the lowest hCTR1 level was detected 
in the clone 2 of mock control clones (Fig. 3-1). Therefore, the hCTR1-transfected clone 2 
was selected to represent the overexpressing subline, named as DLD-1/hCTR1, and the empty 
vector-transfected clone 2 was selected as the corresponding mock control subline for further 
quality tests.   
A 
 
 
B 
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Figure 3-1. hCTR1 protein level of selected clones of colorectal cancer DLD-1 cells stably 
transfected with SLC31A1 gene or the corresponding empty vector 
A. Representative immunoblots of hCTR1-transfected clones (hCTR1 clone 1-4) and mock 
clones (mock clone 1 and 2) measured by Western blotting in three independent experiments. 
B. Densitometry analysis of hCTR1 protein levels in four hCTR1-transfected clones and two 
mock clones. The hCTR1 protein level was normalized to the loading control -actin. Data 
represent mean ± SD (n=3).  
To monitor the stability of hCTR1 expression in the DLD-1/CTR1 and the mock control lines, 
hCTR1 protein levels were measured using Western blotting following four additional 
passages of these sublines maintained in fully supplemented culture media containing 250 
μg/ml G418. As shown in Fig. 3-2, the densitometry analysis indicated that the hCTR1 protein 
level of DLD-1/hCTR1 cells was significantly higher than that of mock control cells by ~ 42 
± 10% (P < 0.05), which was consistent with the results of the initial clone selection as 
described above (Fig. 3-1).  
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Figure 3-2. hCTR1 protein level in overexpressing DLD-1/hCTR1 line and mock control 
line 
A. Representative Western blotting results of DLD-1/hCTR1 and mock control cells. B. 
Densitometry analysis of hCTR1 western blot results normalized to -actin. The transferred 
membrane was incubated with an anti-hCTR1 primary antibody (1:2000) and an HRP-
conjugated secondary antibody (1:2000). Data are expressed as mean ± SD (n=3). *P < 0.05 
compared to mock control. 
Based on the validation of stable hCTR1 expression, the DLD-1/hCTR1 subline and mock 
control subline were selected for all subsequent studies.   
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3.3.2 Overexpression of hCTR1 enhances the cytotoxicity of copper chloride in colorectal 
cancer DLD-1 cells  
For the MTT assay, cells were first incubated with CuCl2 at 5, 10, 30, 50, 100, 300, 500 and 
1000 μM for 72 h before performing the assay. The loss of viability of DLD-1/hCTR1 cells 
was significantly higher compared to the mock cells following exposure to increasing 
concentrations of CuCl2 (Fig. 3-3A). The IC50 of CuCl2 was significantly lower in DLD-
1/hCTR1 cells than that in mock cells by approximately 2.7 folds (28.3 ± 2.5 μM vs 76 ± 7.1 
μM, P < 0.05, t-test) (Fig. 3-3B). The selection of CuCl2 concentration ranges was based on 
its cytotoxicity in wild-type DLD-1 cells measured in our pilot experiments.  
 
Figure 3-3. Overexpression of hCTR1 enhances the cytotoxicity of CuCl2 in colorectal 
cancer DLD-1 cells 
A. Growth curves of DLD-1/hCTR1 and mock cells exposed to indicated concentrations of 
CuCl2 for 72 h, followed by the MTT cytotoxicity assay. Curve fitting was carried out using 
non-linear regression function of log (inhibitor) vs. response (three parameters). B. IC50 values 
of CuCl2 in DLD-1/hCTR1 and mock cells. Data points represent mean ± S.D. of three 
independent experiments. * P < 0.05 compared to mock control cells.   
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Next, the CFA was used to measure the sensitivity of DLD-1/hCTR1 cells and mock cells to 
CuCl2. Briefly, cells were exposed to 200, 400 and 800 µM CuCl2   or drug vehicle for 24 h, 
and then cultured in drug-free media for about two weeks to allow colony formation. Similar 
numbers of colonies were formed in vehicle-treated DLD-1/hCTR1 cells and mock control 
cells (263  19 vs 257  13, P > 0.05) (Fig. 3-4). However, a significantly reduced number of 
colonies were detected in DLD-1/CTR1 cells following exposure to 200 and 400 μM CuCl2 
by 54  7 % (P < 0.05) and 92  10 % (P < 0.05), respectively, when compared to the mock 
cells, while no colonies formed in both cell lines following exposure to 800 μM CuCl2. 
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Figure 3-4.  Overexpression of hCTR1 enhances the inhibitory effect of CuCl2 on the 
colony forming ability of colorectal cancer DLD-1 cells 
 A. Representative image of a 6-well plate showing colonies formed in DLD-1/hCTR1 and 
mock control cells following exposure to 200, 400 and 800 μM CuCl2. B. Number of colonies 
formed in DLD-1/hCTR1 and mock cells following exposure to indicated concentrations of 
CuCl2. Data represent mean ± S.D. (n = 3). * P < 0.05 compared to mock control.  
3.3.3 Overexpression of hCTR1 enhances the cytotoxicity of oxaliplatin in colorectal 
cancer DLD-1 cells 
Following the confirmation of functional expression of hCTR1 as described above, DLD-
1/hCTR1 cells were further examined for their sensitivity to oxaliplatin (OXL) in comparison 
with the mock control cells. The MTT assay and CFA were used to evaluate the short and long-
term cytotoxicity of OXL. 
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For the MTT assay, cells were exposed to increase the concentration of OXL from 0.3-300 μM 
for 2 h, and then cultured in drug-free media for 72 h before performing the MTT cytotoxicity 
assay. The cellular viability of DLD-1/hCTR1 cells was significantly reduced by 8.5 ± 2.3% 
to 16 ± 3.6% compared to mock control cells at the concentrations tested (P < 0.05) (Fig. 3-5). 
However, we did not see significant difference between two cell lines at 100 and 300 μM 
(results not presented here).  
 
 
Figure 3-5. Overexpression of hCTR1 enhances the cytotoxicity of oxaliplatin in 
colorectal cancer cells measured by the MTT assay 
 The DLD-1/CTR1 and mock cells were seeded at 5000 cells per well in triplicate or 
quadruplicate in a 96-well plate and exposed to OXL at indicated concentrations before 
performing the MTT assay. Data values represent mean ± SD. (n=3 or 4). *P < 0.05 compared 
to mock control.  
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The results of the CFA of OXL cytotoxicity are shown in Fig. 3-6. Colonies appeared visibly 
fewer in DLD-1/hCTR1 cells than the mock cells when exposed to 3 or 5 μM OXL (Fig. 3-
6A). Upon quantification of colonies, 364 ± 6 and 317 ± 8 colonies formed in drug vehicle-
treated control wells of DLD-1/hCTR1 cells and mock cells respectively. Colony numbers for 
both cell lines reduced upon exposure to increasing concentrations of OXL. The number of 
colony did not change much in DLD-1/hCTR1 cells and mock cells following the treatment of 
cells with 1 μM OXL (348  9 vs 315  7, P > 0.05). However, colony numbers in DLD-
1/hCTR1 cells were significantly reduced by 1.4 folds (221  21 vs 310  2, P < 0.05) 
following exposure to 3 μM OXL as compared to the mock cells. Following exposure to 5 μM 
OXL, the number of colonies in DLD-1/hCTR1 cells were significantly lower compared to the 
mock cells by 1.7 folds (173  9 vs 291  7, P < 0.05) (Fig. 3-6B). However, we did not see 
significant difference in cells treated with 10 and 30 μM OXL as both of these concentrations 
killed all the colonies (results not presented in the figure). 
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Figure 3-6. Overexpression of hCTR1 enhances the inhibitory effect of OXL on the 
clonogenic potential of colorectal cancer DLD-1 cells measured by the CFA 
A. Representative image of a 6 well plate showing colonies formed in DLD-1/hCTR1 and 
mock control cells following exposure to vehicle or 1, 3, 5, 10 and 30 μM OXL. B. Number of 
colonies formed in DLD-1/hCTR1 and mock cells following exposure to vehicle or OXL at 
indicated concentrations. Data are expressed as mean ± SD. (n = 3). * P < 0.05 compared to 
mock cells. 
3.3.4 Overexpression of hCTR1 enhances cellular uptake of oxaliplatin in colorectal 
cancer cells   
No fluorescent signal was detected in DLD-1/hCTR1 cells and mock control cells following 
incubation with FDCPt1 alone (Fig. 3-7A). In contrast, a weak but visible fluorescence signal 
was detected in DLD-1/hCTR1 and mock cells following exposure to 30 μM OXL for 2 h. 
Fluorescence intensity increased in both cell lines following exposure to 30 μM OXL for 6 h, 
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with signal intensity markedly stronger in DLD-1/hCTR1 cells compared to mock cells. Digital 
quantification of fluorescence intensity showed that the signal in DLD-1/hCTR1 cells was 
~1.48-fold higher than that of mock control cells after 6 h (Fig. 3-7B). In addition, FDCPt1-
derived fluorescence signal was mainly localized to the plasma membrane in mock control 
cells, whereas it was predominantly localized to the cytoplasm in DLD-1/hCTR1 cells (Fig. 3-
7A, inserts).  
 
B 
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Figure 3-7. Overexpression of hCTR1 enhances cellular uptake of oxaliplatin in 
colorectal cancer DLD-1 cells 
A. Fluorescent images of DLD-1/hCTR1 and mock cells treated with 100 μM FDCPt1 alone 
or after incubation with 30 μM OXL. OXL-activated FDCPt1 (green). Nucleus marker (blue).  
Mag. 40x. Insert is an enlargement of white-framed area. B. Quantitative analysis of FDCPt 
fluorescence intensity of DLD-1/hCTR1 and mock cells after incubation with 30 μM OXL. 
Data represents mean ± SD. (n = 3). * P < 0.05 compared to mock control cells. Cells were 
treated with 30 μM OXL for 2 and 6 h, and then incubated with 100 μM FDCPt1 for 30 min. 
Images were captured with a fluorescence microscope and analyzed using Image J software.   
3.4 Discussion  
In this study, we demonstrated the positive contribution of human copper transporter hCTR1 
as an uptake transporter of OXL in colorectal cancer cells that stably express recombinant 
hCTR1 via plasmid-based transfection.  
Firstly, we have successfully established a subline of colorectal cancer DLD-1 cells that stably 
express hCtr1 gene (DLD-1/hCTR1) and a corresponding subline as the mock control cells 
that were transfected with the empty vector. The conditions for transfection and selection were 
optimized to obtain resistant clones of DLD-1 cancer cells under the cytotoxic pressure of 
G418. Recombinant hCTR1 protein levels in DLD-1/hCTR1 cells were about 40 % higher 
compared to the levels in mock control cells. This phenotype was consistently maintained over 
several population doublings following additional subculture, based on the verification of 
elevated hCTR1 protein expression in DLD-1/hCTR1 cells. Previously, varying levels of 
hCTR1 have been reported in different types of cancer cells that are transfected transiently or 
stably with constructs containing the hCtr1 gene, such as an ovarian carcinoma cell line [162] 
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and an non-small cell lung cancer cell line [163]. These cell-specific expression differences of 
target gene could be attributable to transfection efficiency, the specific plasmid backbones used, 
as well as endogenous hCTR1 levels. In our study, wild-type DLD-1 colorectal cancer cells 
displayed a discernable level of basal hCTR1 expression, which might limit the expression of 
recombinant hCTR1 in these cells. 
The functional activity of hCTR1 in overexpressing DLD-1/hCTR1 cells was verified by 
measuring their sensitivity to CuCl2, which is a prototype substrate of hCTR1. The cytotoxicity 
of CuCl2 is known to be associated with its cellular accumulation [164,165]. In this study, the 
short-term toxicity of CuCl2 to DLD-1/hCTR1 cells increased approximately by 2.7 folds when 
compared to the mock control cells based on their IC50 values derived from the MTT assay. In 
addition, long-term cytotoxicity of CuCl2 was also increased in DLD-1/hCTR1 cells, based on 
their markedly reduced clonogenic capacity following drug exposure, which was measured by 
the colony forming assay. These data suggest that the elevated cytotoxicity of CuCl2 in DLD-
1/hCTR1 cells was likely induced by hCTR1-mediated increase of cellular Cu uptake.  
The availability of an overexpressing DLD-1/hCTR1 colorectal cancer line was the basis to 
examine the role of hCTR1 in the cellular transport of OXL. Indeed, our results have 
demonstrated that overexpression of hCTR1 significantly increases the cytotoxicity and uptake 
of OXL in DLD-1/hCTR1 cancer cells. Compared to the mock control cells, the short-term 
cytotoxicity of OXL at pharmacologically relevant concentrations increased in DLD-1/hCTR1 
cells by approximately 8.5~16% (P < 0.05), while the long-term toxicity of OXL increased in 
these cells by 1.4~1.7 folds (P < 0.05). This increased sensitivity was likely a direct 
consequence of hCTR1-dependent increased cellular uptake of OXL in DLD-1/ cells by 
approximately 1.5 folds. Compared to the mock control cells, DLD-1/hCTR1 cells displayed 
stronger cellular uptake of OXL in cytoplasm, which suggests a direct contribution of hCTR1 
to the cellular uptake of OXL in these cells.  
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Our results support a positive role of hCTR1 in the cellular transport of OXL in colorectal 
cancer cells, which is consistent with other studies that used hCTR1-overexpressing small cell 
lung cancer cells [166], hCTR1-transfetced HEK293 cells [167], mouse Ctr1-knockout 
embryonic fibroblasts [163] and rCtr1-transfected HEK293 cells [163]. Nevertheless, the 
capacity of hCTR1 overexpression to increase cellular uptake and cytotoxicity of OXL appear 
to differ among different cell types. We observed a 1.4-fold increase in the sensitivity of DLD-
1/hCTR1 cells to OXL compared to the mock cells, whereas others report a 3.3-fold increase 
in HEK293/hCTR1 cells transfected with a similar construct [166,168,169].  
Notably, the capacity of hCTR1 to transport Cu and OXL, and to enhance their cytotoxicity 
appeared to differ in colorectal cancer DLD-1 cells. For example, the sensitivity of DLD-
1/hCTR1 cells to CuCl2 was increased by 2.7 folds, but their sensitivity to OXL was only 
increased by maximally 16% based on the results of the MTT cytotoxicity assay. This 
observation is consistent with a recent study that reports a ~70-fold increased toxicity of CuCl2 
compared to OXL-toxicity in hCTR1-transfected HEK/hCTR1 cells [155].  This may be 
attributable to differences in the uptake between Cu and platinum anticancer drugs. hCTR1-
transfected HEK/hCTR1 cells are reported to accumulate Cu at a ~80-fold higher rate than that 
for taking up OXL (0.33 vs 0.004 nmol/mg protein/min/μM drug) [157]. It may also be 
attributable in part to differences in substrate specificity and affinity to hCTR1, cellular 
capacity of handling and tolerance to excess levels of Cu and Pt [170]. 
The fluorescence probe FDCPt1 was designed to specifically detect monofunctional Pt(II) 
species. OXL can be bio-transformed into numerous pharmacologically active Pt-containing 
species once entering the cell, including the monofunctional monochloro- and monoauqated 
Pt biotransformation products [68,70,73]. In our study, FDCPt1 was successfully used to trace 
the uptake and distribution of OXL-derived monofunctional Pt species in colorectal cancer 
DLD-1/hCTR1 cells and mock control cells. The sensitivity and reproducibility of FDCPt1 
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results were compatible with a previous report where FDCPt1 effectively detects 
monofunctional biotransformation products of OXL, cisplatin and carboplatin in HT-29 and 
Caco-2 colorectal cancer cells [72,171]. We also observed that DLD-1/hCTR1 cells displayed 
strong FDCPt1-associated fluorescence especially with a significant nucleus localization. This 
is supportive of enhanced OXL cytotoxicity, because its main pharmacological activity 
depends on the formation of nucleus DNA-Pt adducts [68,70,73].  
Taken together, this data show for the first-time the capability of hCTR1 to mediate the uptake 
and cytotoxicity of OXL in colorectal cancer cells. Stable expression of recombinant hCTR1 
increased both short-term and long-term cytotoxicity of OXL of DLD-1 colorectal cancer cells. 
Our data demonstrate that overexpression of recombinant hCTR1 enhances the cellular uptake 
of OXL. In particular, the hCTR1-mediated increased uptake of OXL with its cytoplasmic and 
nucleus accumulation of active Pt-containing biotransformation species appeared to contribute 
to the observed increased cytotoxicity in colorectal cancer cells.  
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Chapter 4 Effects of Cu Chelators and Cu chloride on 
Oxaliplatin Cytotoxicity in Colorectal Cancer Cells 
4.1 Introduction  
The results of the Chapter 3 demonstrated a positive role of hCTR1 in the uptake of oxaliplatin 
in colorectal cancer cells that overexpress recombinant hCTR1. Previously, pharmacological 
approaches to achieve this goal involve up regulation of hCTR1 expression in cancer cells, for 
example by Cu chelators [68,70,73]. Cu chelators have been reported to be able to increase 
endogenous hCTR1 protein expression and enhance the anticancer activity of cisplatin, another 
commonly used platinum anticancer drug used in vitro and in vivo preclinical models [172]. 
Cu chelators that are clinically used for the treatment of Wilson’s disease have been reported 
to sensitize cells towards the anticancer activity of cisplatin via hCTR1- or mCtr1-mediated 
transport mechanism. Although, the Cu chelators ammonium tetrathiomolybdate (ATTM) and 
D-penicillamine (D-P) show this effect in human cervical and ovarian cancer cells [68,70,73], 
studies of this type have not been undertaken with OXL or in colorectal cancer cells.  
All these results have set a basis for targeting hCTR1 to enhance the anticancer activity of 
OXL via improving its uptake into cancer cells. However, understanding the endogenous 
expression of copper transporters in appropriate cellular model is a prerequisite towards this 
goal. Therefore, we firstly systematically investigate the endogenous expression of the Cu 
uptake transporter hCTR1 and the copper efflux transporters ATP7A and ATP7B in native 
colorectal cancer cell lines. We selected four colorectal cancer cell lines HCT-15, DLD-1, 
COLO205 and SW620, which have also been included in National Cancer Institute’s NCI-60 
panel for drug screening [154]. In addition, these cell lines represent the primary or metastatic 
subtypes of the disease. DLD-1 and HCT-15 were derived from a primary Dukes’C colorectal 
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carcinoma specimen of the same patient but showing different karyotypes [154]. The SW620 
line was derived from a lymph node metastasis in a patient with Dukes’ C colorectal 
adenocarcinoma [76]. COLO205 was derived from ascetic fluid of a patient with colon 
carcinoma with multiple metastases [79]. COLO205 harbors the BRAF (V600E) mutation, 
whereas KRAS mutations are detected in DLD-1, HCT-15 and SW620 cells [174]. 
Therefore, the aim of this chapter was to investigate the therapeutic value of Cu chelators to 
enhance OXL cytotoxicity in colorectal cancer cells by modulating hCTR1 expression. The 
expression and the localization of copper transporters in the selected cell lines were 
investigated using RT-PCR, Western blotting and immunohistochemistry techniques. The 
cytotoxicity of drugs was measured using the MTT assay as described above. Cellular hCTR1 
protein levels were measured using a reliable Western blotting assay in cancer cells undergoing 
treatment with different drugs and conditions. The effects of Cu chelators on the major Cu 
efflux transporters ATP7A and ATP7B were also measured in contrast with that on hCTR1. 
In addition, the effect of Cu chloride and OXL on hCTR1 expression was measured in 
colorectal cancer cells, since Cu chloride and cisplatin reportedly cause degradation of hCTR1 
in other cancer cell types [173].  
4.2 Experimental design 
4.2.1 Characterization of the expression of copper transporters in colorectal cancer cell  
lines 
Combinations of methods were used to characterize the expression of hCTR1, ATP7A and 
ATP7B in colorectal cancer cell lines including reverse transcription polymerase chain 
reaction (RT-PCR), Western blotting, and immunocytochemistry. All experiments were 
conducted in parallel in order to compare the expression of copper transporters across cell lines.  
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4.2.2 Measurement of the sensitivity of colorectal cancer cell lines to oxaliplatin 
In theory, each of these four cells lines can be utilized as a cellular model for following 
modulation studies involving different chemicals. However, to show the contribution of 
hCTR1, the best model should be the most resistant one, therefore, MTT assay was performed 
to select a relatively OXL resistant cellular model among these cell lines. Technical details 
about the experimental procedures were described in section 2.4.1. In either 72-h or 2-h 
exposure experiments, the OXL dose range was selected to achieve minimal and maximal 
cytotoxicity of the colorectal cancer cell lines and was based on previous cytotoxicity studies 
performed in our lab [165]. 
4.2.3 Studies on the effect of compounds on hCTR1 expression using Western blotting 
Prior to incubation with Cu chelators, CuCl2 and oxaliplatin, DLD-1 cells or SW620 were 
seeded at a seeding density of 105 cells/well in a 12-well plate and cultured for 3 days until a 
~50% of confluence was reached.  
In incubation experiments of copper chelators, DLD-1 cells were then exposed to 30 μM 
ammonium tetrathiomolybdate (ATTM) for 1, 6, 9 and 24 h, 10 μM D-penicillamine (D-P) for 
1, 6 and 16 h, or 50 μM bathocuproinedisulfonic acid disodium salt (BCS) for 1, 16, 24 and 72 
h, respectively.  SW620 cells were exposed to 30 μM ATTM or 50 μM BCS for 1, 6, 9 and 24 
h, respectively, or drug vehicle as controls.   The selection of time points for chelator incubation 
was based on the results of our pilot studies. For example, rapid changes of hCTR1 protein 
expression were noticed in SW620 cells at earlier timepoints (6 h and 9 h). In contrast, DLD-
1 cells required longer incubation times (16 h) to induce apparent protein changes. In addition, 
the timepoint selection was also based on the previous studies performed in other cancer cell 
lines to capture the most possible drug effect on hCTR1 protein levels [73,225,226].  
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In incubation experiments of CuCl2, time points for incubation of DLD-1 cells with 100 μM 
CuCl2 were originally arranged as 1, 6, 9, 16 h. However, they were changed to 2, 4, 8 and 16 
h due to technical error (addition of drug at 1 h missed).  Since study shows the effect of CuCl2 
on the expression of CTR1 tends to be very quick (shorter than 1 h) [76], this 1-h error may 
not cause significant deviation of data measured at two sets of time points. SW620 cells were 
exposed to 100 μM CuCl2 for 1, 6, 9 and 16 h, respectively, or drug vehicle as controls. The 
maximal duration of incubation and concentration of CuCl2 were selected to avoid the potential 
stress to cells. 
In incubation experiments of oxaliplatin (OXL), DLD-1 cells were exposed to 10 μM OXL for 
0.25, 1, 4 and 8 h. SW620 cells were exposed to 10 μM OXL for 1, 6, 9 and 16 h, respectively, 
or drug vehicle as controls.  The selection of short exposure time of 0.25 h for DLD-1 cells 
was based on the results of our pilot study, where we observed a rapid change at this time point 
in DLD-1 cells but not in SW620 cells. This result is also consistent with the current literature 
suggesting that platinum drugs induce an instant change in the level of the hCTR1 protein 
within 15 min in ovarian cancer cells [86]. The selection of 10 μM for OXL was based on its 
pharmacological relevance to the plasma concentrations of OXL in cancer patients (14.6 ± 3.1 
μM) [64]. 
At the end of experimental incubation, cell lysates were prepared for the measurement of 
hCTR1 protein level using the Western blotting analysis as described below.  
4.2.4 Studies on the effect of copper chelators, copper chloride and oxaliplatin on the 
cellular localization of copper transporters using immunocytochemistry 
Prior to incubation with the compounds, DLD-1 or SW620 cells were seeded at a density of 
8x104 cells/well onto a sterile coverslip mounted at the bottom of a 24-well plate. Cells were 
cultured for 2 days to reach ~ 50% confluence, following various experimental incubations as 
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shown below, immunocytochemistry were utilized to capture the possible changes that were 
accompanied with incubation: 
In experiments to determine the effect of copper chelators on ATP7A or ATP7B expression, 
DLD-1 or SW620 cells were then exposed to 50 μM BCS, 30 μM ATTM and 10 μM D-P, for 
up to 24 h. 
In experiments to determine the effect of CuCl2 on the cellular localization of hCTR1, DLD-1 
or SW620 cells were exposed to 20 or 100 M CuCl2 for 2 h.  The short exposure of 2 h was 
chosen based on the literature that suggest this time period is still longer enough to induce the 
alteration of hCTR1 [77]. To study the effect of copper on ATP7A or ATP7B expression, 
DLD-1 cells or SW620 cells were exposed to 100 M CuCl2 for 1, 4 and 16 h, and 6, 24 and 
48 h, respectively. The maximal duration of incubation was also cell line-specific to avoid the 
potential stress caused by CuCl2. 
In experiments to determine the effect of OXL on ATP7A or ATP7B expression, DLD-1 or 
SW620 cells were exposed to 10 M OXL for 0.25, 4 and 8 h, and 1, 6 and 24 h, respectively. 
The time points of incubation were selected to be close to the experimental conditions used to 
study the effect of OXL on the expression of hCTR1 as mentioned in Section 4.2.3.  
Cells were treated in parallel with drug vehicle as control. At the end of incubation, the cellular 
localization of ATP7A or ATP7B was explored using immunocytochemistry staining. 
4.2.5 Toxicity assays of DLD-1 and SW620 cells in the presence of copper chelators or 
copper chloride 
To determine the effect of copper chelators or CuCl2 on the cytotoxicity of colorectal cancer 
cells, DLD-1 or SW620 cells were seeded at a seeding density of 6000 cells/well in a 96-well 
plate in a triplicate, left overnight for attachment and incubated with 50 μM BCS or 30 μM 
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ATTM or 100 μM CuCl2 for 16, 6 and 2 h respectively, followed by exposure to 100 M OXL 
alone for 2 h and a 72-h drug free culture before performing MTT assay. Cells were treated in 
parallel with drug vehicle as control.  
Shorter exposure (2 h) is used for observing the drug uptake and toxicity for oxaliplatin, as the 
initial stage of the drug uptake process is more likely mediated by drug transporters. Whereas, 
the drug uptake process becomes more dominated by passive diffusion mechanisms with 
extensive incubation [28]. Higher concentration was selected for oxaliplatin (100 μM), because 
it is the minimal drug level to achieve measurable toxicity with such a short incubation time, 
which has been shown in our pilot experiments and by others [70]. 
4.3 Results 
4.3.1 Endogenous expression of Cu transporters hCTR1, ATP7A and ATP7B in human 
colorectal cancer cells  
4.3.1.1 Cu uptake transporter hCTR1  
hCTR1 mRNA levels were detected in DLD-1, SW620, HCT-15, and COLO205 cells by RT-
PCR (Fig. 4-1A). The results of two independent experiments are reproducible and consistent 
with the hCTR1 mRNA levels reported for these cell lines in the NCI60 cancer cell expression 
dataset (U133A) [190], which is accessible via the BioGPC gene portal [191]. The density of 
electrophoretic bands of PCR products for hCTR1 on agarose gel appeared to be similar across 
the cancer cell lines, despite the semi-quantitative nature of the RT-PCR assay. 
We next measured hCTR1 protein levels by Western blotting using an anti-hCTR1 antibody. 
In all four cancer cell lines hCTR1 could be clearly detected as a protein band of ~35 kDa. In 
three independent experiments, the density of hCTR1 bands, normalized to β-actin, was similar 
for the four cell lines (Fig. 4-1B).  
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Figure 4-1. Endogenous expression of hCTR1 in human colorectal cancer cells 
A. Detection of hCTR1 mRNA levels by RT-PCR in two independent experiments. B. 
Detection of hCTR1 protein levels measured by Western blotting in three independent 
experiments. GAPDH gene and β-actin protein were probed, respectively as loading controls.  
We then performed immunofluorescence using the same primary hCTR1 antibody to visualize 
the cellular distribution of hCTR1. Immunoreactivity to hCTR1 was detected in all cell lines, 
albeit with slightly different distribution patterns and intensities (Fig. 4-2). Overall, a stronger 
hCTR1 immunoreactivity was associated with the plasma membrane of DLD-1 and SW620, 
HCT-15 cells compared to COLO205, whereas diffuse, weak but stable immunostaining was 
observed in the cytoplasm of all cell lines, without distinct compartment-specific localization. 
When excluding Triton X-100, a cell membrane permeabilizing reagent, from the 
immunostaining protocol, hCTR1 immunoreactivity exclusively localized to the cell surface 
of DLD-1, SW620, HCT-15 and COLO205 cells (Fig. 4-2).  
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Figure 4-2. Cellular distribution of hCTR1 protein in colorectal cancer cells 
DLD-1, SW620, HCT-15 and COLO205 cells were treated with or without permeabilizing 
agent Triton X-100 before stained with the primary anti-hCTR1 antibody and Alexa Fluor® 
488-conjugated secondary antibody (green).  DAPI (blue) was used as nucleus marker. Scale 
bars represent 10 μm.  
The hCTR1 immunoreactivity was found to co-localize with that of Na+/K+-ATPase protein, 
a specific plasma membrane marker (Fig. 4-3).  
 
 
Figure 4-3. Localization of hCTR1 at plasma membrane of colorectal cancer cells 
Immunofluorescent co-staining was performed in SW620 cancer cells using an anti-hCTR1 
primary antibody, an anti-Na+/K+ ATPase primary antibody, and the corresponding Alexa 488- 
and Alexa 594-conjugated secondary antibodies. Partial co-localization (yellow) was observed 
 89 
between hCTR1 immunoreactivity (green) and Na+/K+ ATPase immunoreactivity (red). DAPI 
(blue) was used as nucleus marker. Scale bars represent 10 μm. 
4.3.1.2 Cu efflux transporter ATP7B  
Next, we characterized the expression of Cu efflux transporter ATP7B in colorectal cancer 
cells. The mRNA of ATP7B was detected abundantly across all the four cell lines by RT-PCR 
analysis without apparent differences between cell lines (Fig. 4-4A). A PCR amplicon of 
446bp corresponding to ATP7B mRNA was shown consistently in two independent 
experiments. Moreover, Western blotting identified a clear but a relatively weak protein band 
with the expected molecular weight of ~165 kDa in DLD-1, SW620, HCT-15 and COLO205 
cancer cells using a specific anti-ATP7B antibody (Fig. 4-4B). The intensity of ATP7B protein 
band appeared to be much lower than that of hCTR1. 
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Figure 4-4. Endogenous expression of ATP7B in colorectal cancer cells 
A. Detection of ATP7B mRNA expression by RT-PCR. B. Detection of ATP7B protein levels 
by the Western blotting of DLD-1, SW620, HCT-15 and COLO205 cancer cell extracts. 
GAPDH gene and β-actin protein were probed, respectively as loading controls.  
The immunoreactivity of ATP7B was detected in all colorectal cancer cell lines, namely, DLD-
1, SW620, HCT-15 and COLO205 cells (Fig. 4-5). Relatively strong plasma membrane 
immunoreactivity for ATP7B was detected in all four cell lines (Fig. 4-5A), which was further 
confirmed by co-localization of ATP7B with the plasma membrane marker Na+/K+ ATPase in 
SW620 cancer cells (Fig. 4-5B).  
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Figure 4-5. Cellular distribution of ATP7B in colorectal cancer cells 
A. Immunofluorescence detection of ATP7B (green) in DLD-1, SW620, HCT-15 and 
COLO205 cancer cells. B. Immunofluorescence co-staining of ATP7B (green) and Na+/K+ 
ATPase (red) indicates co-localization (yellow). Species-specific Alexa 488- or Alexa 594-
conjugated secondary antibodies were used with DAPI (blue) as a nucleus marker. Scale bars 
represent 10 μm. 
4.3.1.3 Cu efflux transporter ATP7A  
ATP7A mRNA was detected across the four colorectal cancer cell lines DLD-1, SW620, HCT-
15 and COLO205, with no apparent differences between cell lines (Fig. 4-6A). A PCR product 
with an amplicon size of 322 bp was consistently detected in two independent experiments. 
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The intensity of the amplified ATP7A cDNA bands appeared to be lower than that of hCTR1 
and ATP7B, after normalizing to the internal loading control GAPDH.  
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Figure 4-6. Endogenous expression of ATP7A in colorectal cancer cells 
 A. ATP7B mRNA detected by RT-PCR. B. ATP7A protein levels detected by Western 
blotting in DLD-1, SW620, HCT-15 and COLO205 cancer cells. GAPDH gene and β-actin 
protein were probed, respectively as loading controls.  
Next, we measured ATP7A protein levels using Western blotting. As shown in Fig 4-6B, a 
protein band with the expected molecular weight of ~165 kDa was identified in DLD-1, 
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SW620, HCT-15 and COLO205 cancer cells using a previously validated antibody [192]. The 
intensity of this band appeared to be similar across all cell lines, but lower than that of hCTR1. 
As shown in Fig. 5-7A, ATP7A was detected in all cell lines with different distribution patterns 
using immunofluorescence detection. Plasma membrane-associated immunoreactivity 
appeared to be stronger in DLD-1, HCT-15 and COLO 205 than SW620 cells, while all lines 
showed diffuse, granular and cytoplasmic staining (Fig. 4-7A). This staining pattern was 
confirmed by confocal microscopy, where in addition to xy-images also the z-section views 
were acquired (Fig. 4-7B). 
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Figure 4-7. Cellular distribution of ATP7A protein in colorectal cancer cells 
A. Fluorescence immunocytochemistry showing ATP7A immunoreactivity (red) in DLD-1, 
SW620, HCT-15 and COLO205 cancer cells. B. Confocal microscopic images of ATP7A (red) 
and DAPI (blue) in cancer cells, xy-plane (top) and z-sections (bottom stripes) are shown. 
Scale bar represents 5 μm. 
4.3.2 Differential sensitivity of colorectal cancer cell lines to oxaliplatin  
These cell lines display significant differences in their sensitivity to OXL following a 72-h 
drug exposure, with IC50 values of 0.8 ± 0.2, 3.2 ± 0.2, 15.4 ± 2.3 and 15 ± 3.1 μM for SW620, 
COLO205, DLD-1 and HCT-15, respectively (Fig. 4-8). DLD-1, HCT-15 and COLO205 cells 
were significantly more resistant to OXL by about 19, 18, and 4 folds, respectively, when 
compared to the most sensitive cell line tested, SW620.    
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Figure 4-8.  Cytotoxicity of oxaliplatin (OXL) in colorectal cancer cells following a 72 h-
drug exposure 
A. Viability curves of cancer cells following exposure to a range of OXL concentrations. B. 
Comparison of IC50 values of OXL in different cell lines. * P < 0.05 compared to SW620. 
Cells were treated with OXL at varying concentrations for 72 h before viability was measured 
by the MTT assay. Data represent mean ± SD (n = 3 or 4).  
Moreover, we measured OXL cytotoxicity under conditions of short-term drug exposure (2 h-
exposure), to select appropriate, non-toxic concentrations of OXL for the following incubation 
studies. These cell lines display significant differences in their sensitivity to OXL following a 
2-h drug exposure, with IC50 values of 12.4 ± 5.6, 87.4 ± 11.8, 350.7 ± 35.5 and 241.8 ± 27.8 
μM for SW620, COLO205, DLD-1 and HCT-15, respectively (Fig. 4-9B). DLD-1, HCT-15 
and COLO205 cells were significantly more resistant to OXL by about 28, 20, and 7 folds, 
respectively, when compared to the most sensitive cell line tested, SW620.    
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In addition, the ranking of sensitivity of these cell lines to OXL after a 2 h-exposure was the 
same as the ranking following a 2 h-exposure. DLD-1 was the least sensitive cell line, followed 
by HCT-15 and COLO205, whereas SW620 was the most sensitive line to OXL (Fig. 4-9).  
 
Figure 4-9. Short-exposure cytotoxicity of oxaliplatin (OXL) in colorectal cancer cells 
Cells were exposed to 3, 10, 30 or 100, 300 or 500 µM OXL for 2 h, followed by a 72-h drug-
free culture before preforming the MTT assay. Data represent mean ± SD. (n3). * P < 0.05 
compared to drug vehicle-treated control cells (One-way ANOVA). 
The reason for the different sensitivity of these colorectal cell lines to OXL is unclear but it is 
likely attributable to their intrinsic genetic and phenotypic characteristics. The selection of the 
two colorectal cancer cell lines DLD-1 and SW620 for this study was based on their abundant 
endogenous expression of hCTR1 and distinctive sensitivity to oxaliplatin. The colorectal 
cancer DLD-1 cells and SW620 cells were selected to represent a relatively resistant cell line 
and a sensitive cell line, respectively, to allow the subsequent comparative studies of the 
contribution of hCTR1 transporter. In addition, the selection of these two colorectal cancer cell 
lines was considered based on their origins. The DLD-1 cell line was derived from a primary 
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colorectal cancer tissue, whereas the SW620 line from tumor tissues of a metastatic site in the 
lymph node [76, 154].  
4.3.3 Cu chelators up regulate hCTR1 expression in DLD-1 cells and SW620 cells 
colorectal cancer 
The results of Chapter 3 demonstrated the presence of Cu transporters in human colorectal 
cancer cells and a positive role for the overexpression of recombinant hCTR1 in the cellular 
uptake of OXL. This prompted us to test whether Cu chelators could up regulate hCTR1 
expression and thereby enhance OXL sensitivity in colorectal cancer cells. For this purpose, 
we tested the clinically used ammonium tetrathiomolybdate (ATTM), D-penicillamine (D-P), 
and an experimental Cu-chelating compound called bathocuprione disulfonate (BCS). The 
kinetic effects of Cu chelators on hCTR1 protein expression were measured by Western 
blotting using the colorectal cancer cells DLD-1 and SW620. The concentrations and 
incubation periods of these Cu chelators were nontoxic based on the prior cytotoxicity studies.  
DLD-1 cells were exposed to 30 μM ATTM for 1, 6, 9 and 24 h, 10 μM D-P for 1, 6 and 16 h, 
or 50 μM BCS for 1, 16, 24 and 72 h, followed by the preparation of cell lysates for Western 
blotting analysis. The results of three independent experiments were relatively reproducible 
for the Cu chelators (Fig. 4-10 A, B & C). hCTR1 protein increased over time in DLD-1 cancer 
cells and the increase became statistically significant after a 6-h exposure to 30 μM ATTM 
(132 ± 12.5% of control, P < 0.01, ANOVA, Fig. 5-2A), 10 μM D-P (121 ± 13.3% of control, 
p < 0.01, ANOVA, Fig. 4-10B) or after 16 h of 50 μM BCS (124 ± 4.4% of control, P < 0.01, 
ANOVA, Fig. 4-10C). Expression of hCTR1 returned to control levels following extended 
periods of exposure to D-P and BCS in contrast to ATTM that induced increased expression 
up to 24 h.  
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Figure 4-10. Temporal effects of Cu chelators on hCTR1 protein levels in colorectal 
cancer DLD-1 cells 
A. Western blotting analysis of hCTR1 protein levels in DLD-1 cells following exposure to 
ATTM. B. Western blotting analysis of hCTR1 protein levels in DLD-1 cells following 
exposure to D-P. C. Western blotting analysis of hCTR1 protein levels in DLD-1 cells 
following exposure to BCS. Cells were exposed to 30 μM ammonium tetrathiomolybdate 
(ATTM) (A), 10 μM D-penicillamine (D-P) (B) or 50 μM BCS (C) for the indicated time 
periods, followed by the Western blotting analysis indicated with the representative blotting 
bands from one of three independent experiments. Bar graphs indicate densitometric 
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measurement of hCTR1 protein level normalized to -actin. Data represent means ± SD (n=3). 
* P < 0.05, ** P < 0.01 compared to control (ANOVA). 
In addition, SW620 cells were exposed to 30 μM ATTM for 1, 6, 9 and 24 h or 50 μM BCS 
for 1, 6, 9 and 24 h, followed by the preparation of cell lysates for Western blotting analysis. 
As shown in Fig. 4-11, hCTR1 protein levels increased significantly after exposure to 30 μM 
ATTM for 6 h (P < 0.05 compared to control, ANOVA, Fig. 4-11A) or 50 μM BCS for 9 h (P 
< 0.05 compared to control, ANOVA, Fig 4-11C). hCTR1 protein levels then returned to the 
control levels following drug exposure over 6 h. The results were relatively consistent among 
the three independent experiments.  
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Figure 4-11. Temporal effects of Cu chelators on hCTR1 protein levels in colorectal 
cancer SW620 cells 
A. Western blotting analysis of hCTR1 protein levels in SW620 cells following exposure to 
ATTM. B. Western blotting analysis of hCTR1 protein levels in SW620 cells following 
exposure to BCS. Cells were exposed to 30 μM ammonium tetrathiomolybdate (ATTM) (A) 
or 50 μM BCS (B) for indicated time period, followed by the Western blotting analysis 
indicated with the representative blotting bands from one of three independent experiments. 
Bar graphs indicate densitometric measurement of hCTR1 protein level relative to -actin. 
Data represent as means ± SD (n=3). * P < 0.05, ** P < 0.01 compared to control (ANOVA).  
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4.3.4 Cu chelators enhance oxaliplatin cytotoxicity in DLD-1 cancer cells, but not SW620 
cancer cells 
To examine whether the up regulation of hCTR1 by Cu chelators could be translated into 
enhanced OXL cytotoxicity, we further compared the cell killing capacity of OXL with or 
without pre-incubation with Cu chelators at indicated concentrations and time periods in the 
colorectal cancer cells DLD-1 and SW620.  
As shown in Fig. 4-12A-B for DLD-1 cells, there was no significant loss of cell viability 
observed after cells were exposed to 50 μM BCS alone for 16 h (96 ± 0.6% of control, P > 
0.05, ANOVA, Fig. 4-12A) or 30 μM ATTM alone for 6 h (93 ± 6% of control, P > 0.05 
compared to control, ANOVA, Fig. 4-12B). Incubation of DLD-1 cells with 100 M OXL 
alone for 2 h displayed significant loss of viability in both experiments (67 ± 8% of control, 
Fig. 4-12A; 87 ± 1.2% of control, Fig. 4-12B) (P < 0.05 compared to control, ANOVA). 
Interestingly, OXL-induced loss of viability was further increased by pre-incubation of DLD-
1 cells with 50 μM BCS for 16 h (80 ± 2.7% of control, P < 0.05 compared to OXL alone, 
ANOVA, Fig. 4-12A) or 30 μM ATTM for 6 h (67 ± 1.2% of control, P < 0.05 compared to 
OXL alone, ANOVA, Fig. 4-12B).  
In SW620 cells, there was no significant loss of cell viability after cells were exposed to 50 
μM BCS alone for 16 h (92.7 ± 3.5% of control, P > 0.05, ANOVA, Fig. 4-12C) or 30 μM 
ATTM alone for 6 h (93.3 ± 1.7% of control, P > 0.05, ANOVA, Fig. 4-12D). Incubation of 
SW620 cells with 100 M OXL alone for 2 h displayed significant loss of viability in both 
experiments (56.9 ± 1.3% of control, Fig. 5-5C; 53.2 ± 0.8% of control, Fig. 4-12D) (P < 0.05 
compared to control, ANOVA). OXL-induced cytotoxicity was not altered after pre-incubation 
of SW620 cells with 50 μM BCS for 16 h (58.7 ± 1.2% of control, P > 0.05 compared to OXL 
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alone, AVOVA, Fig. 4-12C) or 30 μM ATTM for 6 h (57.4 ± 0.6% of control, P > 0.05 
compared to OXL alone, Fig. 4-12D).   
 
 
 
 
 
Figure 4-12. Cu chelators potentiate oxaliplatin (OXL) cytotoxicity in colorectal cancer 
DLD-1 cells, but not SW620 cells 
A. Cellular viability of DLD-1 cells following exposure to BCS and OXL alone or in 
combination. B. Cellular viability of DLD-1 cells following exposure to ATTM and OXL 
alone or in combination. C. Cellular viability of SW620 cells following exposure to BCS and 
OXL alone or in combination. D. Cellular viability of SW620 cells following exposure to 
ATTM and OXL alone or in combination. Cells were pre-incubated with 50 μM BCS for 16 h 
or 10 μM ATTM for 6 h, followed by a 2-h incubation with 100 μM OXL and a 72-h drug-
 106 
free culture before performing a MTT cytotoxicity assay. Data represent as mean ± SD (n≥4). 
* P < 0.05, NS, not significant, ANOVA. 
4.3.5 Cu chelators do not alter expression pattern of ATP7A and ATP7B in colorectal 
cancer cells  
Maintenance of cellular Cu homeostasis relies on concerted functionality of Cu uptake 
transporter hCTR1 and Cu efflux transporters ATP7A or ATP7B [76]. We therefore 
determined whether Cu chelators also influence the expression of ATP7A and ATP7B in the 
colorectal cancer cells DLD-1 and SW620.  
Immunoreactivity against ATP7A in DLD-1 and SW620 cells was mainly localized to the 
cytoplasm and plasma membrane. The expression density and pattern of ATP7A staining 
appeared to be unaltered in both cell lines following exposure to 50 μM BCS, 30 μM ATTM 
and 10 μM D-P over the indicated time periods (Fig. 4-13).   
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Figure 4-13. Cu chelators do not alter the expression of ATP7A in colorectal cancer DLD-
1 and SW620 cells 
A. Representative immunocytochemistry images of DLD-1 cancer cells incubated with 50 μM 
BCS, 30 μM ATTM or 10 μM D-P for indicated time period. B.  Representative 
immunocytochemistry images of SW620 cancer cells incubated with 50 μM BCS, 30 μM 
ATTM or 10 μM D-P for indicated time period. Immunofluorescence staining was performed 
to visualize cellular ATP7A immunoreactivity (red) using an anti-human ATP7A primary 
antibody and an Alexa 594-conjugated secondary antibody. Nuclei were stained with DAPI 
(blue). Scale bars represent 10 m. 
Under drug vehicle-treated control conditions, ATP7B immunoreactivity was mainly localized 
to the cytoplasm and the plasma membrane in DLD-1 cells (Fig. 4-14A) and SW620 cells (Fig. 
4-14B). The staining intensity and distribution patterns of ATP7B appeared not to be altered 
by the incubation of DLD-1 cells (Fig. 4-14A) and SW620 cells (Fig. 4-14B) with 50 μM BCS 
for 1, 2 and 24 h, 30 μM ATTM for 6 and 24 h, and 10 μM D-P for 6 and 24 h, respectively. 
 108 
 
 
 
 
 109 
Figure 4-14. Cu chelators do not alter the expression of ATP7B in the colorectal cancer 
cells DLD-1 and SW620 
A. Representative images of ATP7B immunofluorescence of DLD-1 cancer cells exposed to 
50 μM BCS, 30 μM ATTM or 10 μM D-P for indicated time periods. B. Representative images 
of immunocytochemistry of SW620 cancer cells exposed to 50 μM BCS, 30 μM ATTM or 10 
μM D-P for indicated time periods. Immunofluorescence detection of ATP7B (green) 
employed a primary anti-human ATP7B antibody and an Alexa 488-conjugated secondary 
antibody. DAPI was used as nucleus marker (blue). Scale bars represent 10 m. 
4.3.6 Cu chloride does not alter the expression of Cu transporters and oxaliplatin 
cytotoxicity in colorectal cancer cells  
Altered levels and distribution patterns of the Cu transporters hCTR1, ATP7A and ATP7B 
have been reported in response to Cu overloading for some cell types. Extracellular Cu 
overload induces internalization and degradation of hCTR1 in some cell types, such as in the 
breast cancer cell line PMC42-LA [79], hCTR1-overexpresing human embryonic kidney cells 
(HEK293/hCTR1) [174], but not in human cervical cancer cell line HeLa, Caco-2 colon 
carcinoma cells or T47D breast cancer cells [36]. Some cell lines show trafficking of ATP7A 
and ATP7B towards the plasma membrane after exposure to elevated extracellular Cu levels, 
such as HeLa cells [175] and 2008 ovarian cancer cells [66], whereas other cell lines do not 
show this response, such as the A2780 ovarian cancer cells, and HepG2 human liver cancer 
cells [176]. In this study, we have examined whether addition of CuCl2 could change the 
expression levels or distribution patterns of Cu transporters in the colorectal cancer cell lines 
DLD-1 and SW620.  
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As shown in Fig. 4-15, hCTR1 protein level did not change over time in DLD-1 h (Fig. 4-15A) 
and SW620 cells (Fig. 4-15B) exposed to 100 μM CuCl2 at any time point. There was only a 
marginal reduction of hCTR1 in DLD-1 cells following exposure to CuCl2 for 16 h (85.9 ± 
1.9%), but this trend did not reach statistical significance (P > 0.05 compared to control, 
ANOVA). Meanwhile, the immunostaining density and patterns of hCTR1 were not affected 
by exposure of DLD-1 and SW620 cells respectively to 20 and 100 μM CuCl2 for 2 h (Fig. 4-
15C). 
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Figure 4-15. Cu chloride does not change the expression level and patterns of hCTR1 in 
DLD-1 and SW620 colorectal cancer cells 
A. Western blotting analysis of hCTR1 protein levels in DLD-1 cells following exposure to 
100 μM CuCl2 for up to 16 h. B. Western blotting analysis of hCTR1 protein levels in SW620 
cells following exposure of the cells to 100 μM CuCl2 for up to 16 h. Bar graphs indicate the 
relative expression level of hCTR1 normalized to -actin by densitometric analysis. Data 
represent mean ± SD (n=3 independent experiments). C. Cellular distribution of hCTR1 
immunofluorescence (green) in DLD-1 and SW620 cells following exposure to 20 M or 100 
M CuCl2 for 2 h, using a primary anti-hCTR1 antibody and an Alexa 488-conjugated 
secondary antibody. DAPI was used as nucleus marker (blue). Scale bars represent 10 m. 
We further tested the effect of CuCl2 on the expression of the Cu efflux transporters ATP7A 
or ATP7B in colorectal cancer cells. As shown in Fig. 4-16, the immunoreactivity against 
ATP7A or ATP7B was detectable and localized predominantly to the cytoplasm and the 
plasma membrane in both cell lines. The expression pattern and staining intensities of ATP7A 
and ATP7B appeared not to be altered after exposure of DLD-1 cells to 100 M CuCl2 for 1, 
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4 and 16 h respectively (Fig. 4-16A). The same lack of response was observed for ATP7A 
after exposure of SW620 cells to 100 M CuCl2 for 6, 24 and 48 h respectively (Fig. 4-16B). 
A  
 
B 
 
 
Figure 4-16. Copper chloride does not alter the expression of ATP7A and ATP7B in 
DLD-1 and SW620 colorectal cancer cells 
A. Representative immunofluorescence images of cellular ATP7A (red) and ATP7B (red) 
distribution in DLD-1 cells after exposure to 100 M CuCl2 for 1, 4 and 16 h. B. Representative 
images of cellular distribution of ATP7A immunofluorescence (red) in SW620 cells after 
exposure to 100 M CuCl2 for 6, 24 and 48 h. Immunofluorescence was performed using 
 113 
primary anti-ATP7A or anti-ATP7B antibodies, and an Alexa 594 or Alexa 488-conjugated 
secondary antibody. DAPI was used as nucleus marker (blue).  Scale bars represent 10 m. 
We next examined whether CuCl2 could influence OXL cytotoxicity in colorectal cancer cells. 
As shown in Fig. 4-17A, DLD-1 cancer cells displayed no reduced viability after incubation 
with 100 μM CuCl2 for 2 h, but a significant loss of viability after exposure to 100 μM OXL 
alone (65.9 ± 1.4%, P < 0.05 compared to control, ANOVA). Pre-incubation with CuCl2 did 
not alter OXL-induced cytotoxicity (64.4 ± 0.9%. P > 0.05 compared to OXL alone). As shown 
in Fig. 4-17B, SW620 cancer cells also displayed no loss of viability after incubation with 100 
μM CuCl2 for 2 h, but a significant loss of viability after exposure to 100 μM OXL alone (37.4 
± 1.9%, P < 0.05 compared to control, ANOVA). Similar to the DLD-1 cells, pre-incubation 
with CuCl2 did not alter OXL-induced cytotoxicity (37.7 ± 2.2%. P > 0.05, compared to OXL 
alone, ANOVA). 
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Figure 4-8. Cu chloride does not alter oxaliplatin (OXL) cytotoxicity in colorectal cancer 
cells 
A. Cell viability of DLD-1 cancer cells following exposure to CuCl2, OXL alone or in 
combination. B. Cell viability of SW620 cancer cells following exposure to CuCl2, OXL alone 
or in combination. Cells were pre-incubated with 100 μM CuCl2 for 2 h followed by a 2 h-
incubation with 100 μM OXL and a 72-h drug free culture before performing MTT viability 
assay. Cells were exposed to drug vehicle as control. Data represent mean ± SD (n = 3 or 4). * 
P < 0.05. NS: not significant (ANOVA). 
4.3.7. Effects of oxaliplatin on the expression of hCTR1, ATP7A and ATP7B in colorectal 
cancer cells 
Cisplatin, another common platinum anticancer drug, has been reported to interact with the 
expression of the Cu uptake transporter hCTR1 [177] and Cu efflux transporters ATP7A and 
ATP7B [91,92] in ovarian cancer cells. In this study, we therefore examined whether 
oxaliplatin (OXL) could also influence the expression of hCTR1, ATP7A and ATP7B in 
colorectal cancer DLD-1 and SW620 cells by two different methods.  
In DLD-1 colorectal cancer cells, hCTR1 protein increased in a time dependent manner, which 
became statistically significant following an exposure to 10 μM OXL for 4 h (118.7 ± 4.3%, 
P < 0.05 compared to control, ANOVA). Subsequently, hCTR1 protein levels appeared to 
return to control levels after 8-h OXL exposure (Fig. 4-18A). The results were reproducible 
among three independent experiments. 
In SW620 colorectal cancer cells, there was a trend towards increased hCTR1 protein level 
following exposure of cells to 10 μM OXL for 1 h (116.1 ± 0.5%, P > 0.05 compared to control, 
ANOVA) and 6 h (116.6 ± 2.8%, P > 0.05 compared to control, ANOVA), which however did 
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not reach statistical significance. hCTR1 protein level then appeared to return to control levels 
following exposure to OXL for exposure periods over 9 h (Fig. 4-18B). The results were 
reproducible among three independent experiments. 
A 
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Figure 4-9. Oxaliplatin (OXL) increases hCTR1 protein level in colorectal cancer cells  
A. Western blotting analysis of hCTR1 protein level in DLD-1 cancer cells exposed to OXL 
for indicated time period. B. Western blotting analysis of hCTR1 protein level in SW620 
cancer cells exposed to OXL for indicated time period. Cells were incubated with 10 μM 
OXL for indicated time periods, followed by Western blotting analysis indicated with the 
representative blotting bands from one of three independent experiments.  Relative hCTR1 
levels were normalized to -actin. Data represent means ± SD of three independent 
experiments. * P < 0.05 compared to control (ANOVA).  
In addition, the influence of OXL on ATP7A and ATP7B expression was examined using 
immunofluorescence staining. Intensity and patterns of ATP7A and ATP7B staining did not 
show apparent changes in DLD-1 cells following incubation of the cells with 10 M OXL for 
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0.25, 4 and 8 h (Fig. 4-19A). In these cells, the immunoreactivity of ATP7A and ATP7B was 
localized to the cytoplasm and the plasma membrane.  Likewise, the staining intensity and 
patterns of ATP7A also appeared to be unaltered by exposure of SW620 cells to 10 M OXL 
for 1, 6 and 24 h (Fig. 4-19B). In SW620 cancer cells ATP7A immunoreactivity was 
predominantly cytoplasmic (Fig. 4-19B). 
A 
 
B 
 
Figure 4-10. Oxaliplatin (OXL) does not alter the expression pattern and intensity of Cu 
efflux transporters ATP7A and ATP7B in colorectal cancer cells 
A. Representative images of ATP7A (red) and ATP7B (green) immunofluorescence in DLD-
1 cancer cells exposed to OXL for 0.25, 4 and 8 h. B. Representative images of ATP7A (red) 
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immunofluorescence in SW620 cancer cells exposed to OXL for 1, 6 and 24 h. Cells were 
incubated with 10 M OXL for indicated time periods, followed by performing fluorescent 
detection using primary anti-ATP7A and anti-ATP7B antibodies and Alexa 488- or Alexa 594-
conjugated secondary antibodies. Nuclei were stained with DAPI (blue). Scale bars represent 
10 m. 
 
4.4 Discussion  
We have systematically studied the expression of Cu transporters hCTR1, ATP7A and ATP7B 
in colorectal cancer cells. Overall, hCTR1 was expressed more abundantly than ATP7A and 
ATP7B in colorectal cancer cells. The results of this chapter have also indicated that all tested 
Cu chelators up regulated hCTR1 protein in a time-dependent manner in colorectal cancer 
DLD-1 and SW620 cells, co-treatment with these Cu chelators enhanced the cytotoxicity of 
OXL in DLD-1 colorectal cancer cells, which is likely a consequence of increased hCTR1-
mediated cellular uptake of platinum. 
Firstly, hCTR1 mRNA and protein were detected abundantly in colorectal cancer DLD-1, 
SW620, HCT-15 and COLO205 cells by RT-PCR, Western blotting analysis and fluorescence 
immunocytochemistry. An hCTR1 band of high density with the expected molecular weight 
was detected across all cell lines without apparent differences in abundance. The distribution 
pattern of hCTR1 appeared similar among the cell lines. Predominant plasma membrane 
localization was demonstrated in DLD-1, SW620 and HCT-15 cells with more diffuse 
cytoplasmic staining, whereas COLO205 cells displayed mainly cytoplasmic staining with 
weaker plasma membrane staining. It is unclear whether the difference in hCTR1 distribution 
is related to the different origins from which these colorectal cancer cell lines were derived, 
such as the primary or metastatic sites. Cell type-specific subcellular localization of hCTR1 
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has been reported previously, such as the plasma membrane of HT29 colon cancer cells and 
A2780 ovarian cancer cells [193], cytoplasmic vesicular compartments and perinucleus region 
in Caco2 cells, HeLa cervical carcinoma cells, A549 and H441 lung carcinoma cells, and 
HepG2 hepatocellular carcinoma cells [194]. The biological significance of high basal levels 
of hCTR1 expression in colorectal cancer cells is unclear, but it may be related to their high 
demand of Cu to maintain elevated Cu levels [195] that are necessary for the function of 
superoxidase dismutase [196] and several pro-angiogenic proteins, such as vascular 
endothelial growth factor [197], basic fibroblast growth factor [198] and interleukin-8 [199]. 
Maintenance of cellular Cu homeostasis relies on the concerted function of hCTR1 and the 
efflux transporters ATP7A and ATP7B [200]. We detected abundant mRNA for ATP7A and 
ATP7B in DLD-1, SW620, HCT-15 and COLO205 colorectal cancer cells. However, 
measured by Western blot, ATP7A and ATP7B protein levels were much lower compared to 
hCTR1 levels in these cell lines.  Furthermore, ATP7A protein appeared to be expressed more 
profoundly when compared to the minimal expression of ATP7B protein. This suggests that 
ATP7A is the dominant Cu efflux transporter in colorectal cancer cells, but further studies are 
required to substantiate this. Previously, varying levels of ATP7A mRNA and protein are 
reported for colorectal cancer cells [201] and tumor tissues [202-204]. We observed different 
distribution patterns for ATP7A among these colorectal cancer cell lines, with localization to 
plasma membrane and cytoplasm in DLD-1, SW620 and HCT-15 cells, while a diffuse, 
granular and perinucleus staining was detected in COLO205 cells. These findings are 
consistent with previous reports that report ATP7A localization to the trans-Golgi network in 
ovarian, endometrial, cervical and breast cancer cells [205,206]. It is hypothesized that this 
localization indicated a recycling of ATP7A between the trans-Golgi network and the plasma 
membrane under normal culture conditions in Chinese hamster ovary cells [207]. Our 
immunostaining results showed mainly plasma membrane localized staining of ATP7B in 
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these colorectal cancer cells, which is consistent with previous reports [201,203]. Nevertheless, 
the functionality and contribution of ATP7A and ATP7B to Cu homeostasis in colorectal 
cancer cells remains to be determined.  
However, we did not observe the same synergism of these compounds with OXL in SW620 
cancer cells, which suggests a cell-specific effect. Previously, these Cu chelators have been 
reported to enhance cytotoxicity of cisplatin in various cancer cells [70], increase  antitumor 
activity of cisplatin in animal models [178] and improve the clinical response of ovarian cancer 
patients to carboplatin [179]. It is assumed that these effects are a consequence of increased 
hCTR1- or mCtr1-mediated drug uptake. Nevertheless, further studies are required to 
investigate whether hCTR1 is the major uptake transporter in vivo that determines the 
antitumor activity of OXL against colorectal cancer.  
Conversely, in this study, Cu chelators appeared not to alter the expression and distribution of 
the Cu efflux transporters ATP7A or ATP7B in colorectal cancer cells in our study. The 
staining intensity and distribution patterns of ATP7A and ATP7B did not display apparent 
changes between the cytoplasm and the plasma membrane following exposure to 30 μM 
ATTM for 6 h or 50 μM BSC for 16 h, respectively. This is consistent with previous reports 
of a stable plasma membrane staining of ATP7A at the apical and brush-border of duodenal 
enterocytes [180] and stable expression of ATP7B at the apical membrane of rat hepatocytes 
[181], which were unaltered by BCS-induced Cu depletion. Our results however, are in 
contrast to studies that report that BCS enhanced the perinucleus presence of ATP7A in HeLa 
cervical cancer cells [182] and mouse enterocytes [183] as well as ATP7B in HepG2 
hepatocellular carcinoma cells [184] and A2780 ovarian cancer cells [185]. Consequently, 
cellular trafficking of ATP7A and ATP7B needs to be investigated further in colorectal cancer 
cells under different culture and Cu-level conditions. Nevertheless, the enhancement of OXL 
cytotoxicity by Cu chelators, at least in the colorectal cancer cells used in this study, appears 
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to be mediated by their ability to up regulate hCTR1 expression, but not that of the efflux 
transporters ATP7A and ATP7B. 
In addition, we also did not observe any apparent reduction of hCTR1 in the colorectal cancer 
cell lines DLD-1 and SW620 in the presence of excessive extracellular level of Cu for up to 
24 h, which indicates a relatively stable expression of hCTR1 in the presence of varying 
concentrations of Cu. This finding is consistent with a previous report that excessive Cu 
concentrations showed little effect on the cellular localization of endogenous hCTR1 protein 
in Caco-2 colon cancer cells and HeLa cervical cancer cells [36]. In contrast to our data, Cu 
overload is reported to trigger endocytosis, internalization or degradation of hCTR1 from the 
plasma membrane in ovarian cancer cells [186]. The reduction of hCTR1 localized to the 
plasma membrane is thought to be a self-protective response that prevents Cu toxicity by 
excessive hCTR1-mediated Cu uptake [71]. This degradation of hCTR1 has also been 
associated with the resistance to cisplatin in ovarian cancer cells, because proteasome 
inhibitor-mediated prevention of hCTR1 degradation is reported to re-sensitize these resistant 
cancer cells to platinum drugs [187]. The reason for the discrepancy is unclear, but it seems 
likely the consequence of cell type-specific responses that depend on the intrinsic cell type 
differences with regards to capacity of uptake, adaptability and tolerance to extracellular Cu-
overload conditions.  
In this study, Cu overload did not seem to alter the cellular expression and distribution patterns 
of ATP7A or ATP7B. The DLD-1 and SW620 cancer cells did not display apparent changes 
of plasma membrane or cytoplasmic immunoreactivity of ATP7A and ATP7B, which indicates 
a lack of intracellular trafficking of these transporters. However, ATP7B is known to reside 
normally in the trans-Golgi network of hepatocytes. Therefore, it is likely that ATP7B could 
move rapidly to the apical domain of these cells to increase Cu excretion under conditions of 
high extracellular Cu concentrations and return back to physiological membrane under normal 
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extracellular Cu levels [188]. However, it has to be noted that at least in renal cells ATP7B has 
not shown this type of Cu concentration-dependent trafficking [88], while a concentration-
dependent trafficking mechanism is proposed for ATP7A in intestinal enterocytes and certain 
cancer cells, such as HeLa cervical cancer cells [175]. Therefore, these trafficking mechanisms 
of ATP7A or ATP7B could at least in theory be applicable to colorectal cancer cells. One 
possible explanation for that we did not observe any apparent intracellular movement of these 
transporters could be due to the limitation of the sensitivity of the immunofluorescence 
detection used in our study, which has to be regarded as a largely semi-quantitative method. 
For future studies, the use of confocal microscopy or single-protein detection could be a more 
adequate tool to provide sufficient resolution to trace the intracellular trafficking of these Cu 
transporters in detail.  
Finally, we demonstrated that OXL is able to up regulate hCTR1 protein levels in colorectal 
cancer cells. Expression of hCTR1 protein increased significantly in DLD-1 cells following 
exposure to 10 μM OXL for 4 h. This finding suggests a possible interaction between OXL 
and hCTR1. OXL might behave similar to Cu chelators by competitively inhibiting Cu binding 
to hCTR1, which would directly reduce cellular Cu uptake. Subsequently, this effect is likely 
to trigger a feedback loop to increase hCTR1 expression to compensate for reduced 
intracellular Cu levels. Interestingly, our results are consistent with another study that reported 
a cisplatin-dependent up regulation of hCTR1 expression in ovarian cancer cells, both at the 
mRNA and protein levels. This observation leads the authors to suggest a similar feedback 
loop-based regulatory mechanism [75]. However, cisplatin has also been reported to trigger 
degradation or endocytosis of hCTR1 in other cancer cell types, which is thought to induce 
inactivation of and cellular resistance to cisplatin [189], [187]. Apparently, the exact 
mechanisms of interaction between OXL and hCTR1, and its influence on Cu uptake, needs to 
be investigated in colorectal cancer cells in more detail with appropriate methods.  
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In summary, the results of this chapter have demonstrated that treatment with the clinically 
used Cu chelators, ammonium tetrathiomolybdate and D-penicillamine, can up regulate 
hCTR1 expression and enhance the cytotoxic capacity of OXL in some but not all colorectal 
cancer cell lines. Addition of high level of Cu neither altered hCTR1 protein levels, the 
expression intensities and patterns of the efflux transporters ATP7A and ATP7B nor OXL 
cytotoxicity in colorectal cancer cells. Interestingly, OXL, like Cu chelators, up regulated 
hCTR1 protein expression with no apparent influence on the cellular distribution of ATP7A 
and ATP7B. The anticancer synergism between Cu chelators and OXL will have to be 
evaluated further in additional colorectal cancer cell lines in vitro and in vivo.  
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Chapter 5 Expression of Copper Transporters in 
Human Tumor Tissues of Patients with Colorectal 
cancer 
5.1 Introduction 
Copper transporters seem to be differentially expressed in numerous malignancies compared 
to the matched normal tissues, including the hCTR1 in the cervical tumor of the HPV16/E2 
mice compared to the wild-type cervix [97], ATP7A in the non-small cell lung cancer patients 
[105] and ATP7B in human oral squamous carcinoma [107].   
There is even report that hCTR1 mRNA levels are up regulated in human CRC cell lines 
compared to that of the normal colon mucosa [99]. However, information about their 
expression status in human CRC tissues is scare. Previous results from Chapter 3 have 
demonstrated the positive role of hCTR1 an uptake transporter in the cytotoxicity of OXL. 
Chapter 4 has also proven the feasibility of using copper chelators to enhance the cytotoxicity 
of OXL in CRC cell lines.  However, understanding their expression in CRC is equally 
important to add more translational value to this project. Moreover, their expression status in 
tumour tissues is also likely to become a molecular marker to predict some treatment outcomes 
for OXL-based chemotherapies.  
Therefore, this chapter was undertaken to characterize the expression of Cu transporters in 
colorectal tumor biopsy tissues. Tumor tissue samples and matched normal colon tissues were 
collected from chemotherapy naïve colorectal cancer patients, followed by histological 
examination of the tissues collected using H&E staining, immunohistochemical staining, and 
semi-quantitative analysis of DAB stained images.  
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5.2 Experimental design 
5.2.1 Patient recruitment  
Patients with colorectal cancer were recruited for this study from the Oncology Department of 
the Royal Hobart Hospital in Hobart, Tasmania. The eligibility criteria that were applied for 
patient recruitment included: patients were clinically diagnosed with adenocarcinoma of colon 
or rectum with the confirmation of radiological and histological examinations; patients had no 
history of chemotherapy and were prescribed by a clinical oncologist for surgical tumor 
resection; patients were  18 years old with adequate renal (serum creatinine ≤1.5 mg/dl) and 
liver function (serum transaminases ≤3 times the upper limit of normal). These criteria were 
used to minimize the number of variables that could influence the expression of Cu transporters 
such as age, gender or history of chemotherapy. The study was conducted with the approval 
of the Tasmanian Health and Medical Human Research Ethics Committee (Reference No: 
H0014706). Written informed consent was obtained from all patients included in this study.  
5.2.2 Histological examination of colon samples  
H&E staining was performed to histologically confirm the presence of tumors in the tissues 
collected according to established protocols described in detail in Section 2.8.4. Briefly, 
paraffin-embedded mouse tissue slides were de-waxed by immersion in xylene, absolute 
ethanol, 70% ethanol and 1 min under running tap water, followed by haematoxylin staining, 
differentiation in 1% acetic acid in ethanol, counterstaining using eosin solution and 
dehydration. Dry sections were mounted using a DPX mounting medium and analyzed by light 
microscopy. Particular interests were given to the structure of crypts, the nucleus to cytoplasm 
of the glandular cells and the differentiation degree of the tumors. 
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5.2.3 Evaluation of immuno-histochemical staining and statistical analysis 
DAB-based immunohistochemistry (IHC) was performed on paraffin-embedded or cryo-
sectioned tissues as described in detail in Section 2.9. Following immuno-histochemical 
detection of the expression of copper transporters in human colorectal cancer and normal tissue 
samples, we developed a semi-quantitative analysis method from human colon tissues to 
quantify the DAB-based IHC images in, which is based on a previous report [155]. The method 
is compatible with the open resource digital image analysis software Image J and creates a 
pixel-by-pixel analysis profile of a deconvoluted IHC image and further assigns a score in a 
four-tier system. Detailed procedures and examples were given in Section 5.3.2. Expression of 
the 3 copper transporters in tumor and normal tissues was compared using a paired t-test and 
paired analysis of variance (ANOVA). A p value of 0.05 or less was considered statistically 
significant. 
5.3 Results 
5.3.1 Clinical and histologic information of the matched CRC tissues  
A total of eight patients with colorectal cancer were recruited for this study at the Oncology 
Department of the Royal Hobart Hospital at Hobart, Australia. Patient characteristics are 
summarized in Tab 5-1.  
Table 5-1. Patient characteristics 
Parameter  No of patient (%) 
Gender  
     Male 7 (87.5) 
     Female 1 (12.5) 
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Mean age (range) 74 (65-86) 
Location of primary tumor  
    Sigmold 3 (37.5) 
    Caecal 2 (25) 
    Right colon 3 (37.5) 
Tumor tissue samples and matched adjacent normal colon or rectum were collected from each 
patient. We verified the tissue specimens for all patients histologically using Haematoxylin 
and Eosin (H & E) staining before using them for immunohistochemistry analysis. 
Representative H & E stained images are shown for the normal and tumor colonic tissues that 
were collected from the same patient (Fig. 5-1). Normal colon tissue displayed clearly defined 
mucosa, submucosa, muscularis propria and crypts. In contrast, tumor tissues displayed loss 
of crypt architecture, distorted and complex glandular structures and increased nucleus to 
cytoplasm ratio, with varying degree of differentiation (Fig. 5-1). However, we only selected 
6 tumor specimens that were paired up with the matched normal tissues for the subsequent 
immunohistochemistry studies.  
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Figure 5-1. Histological confirmation of normal and cancerous colon and rectum tissues 
from patients with colorectal cancer 
 Haematoxylin and eosin staining was performed on paraffin-embedded sections of normal and 
tumor tissues. Enlarged insets show normal colonic crypts and crypts with adenocarcinoma. 
Asterisks in tumor section display the loci of adenocarcinoma. Mag. 10x.  
5.3.2 Development of semi-quantitative analysis of DAB stained immunohistochemical 
images  
We developed a semi-quantitative analysis method to quantify the staining intensity of DAB-
based immunohistochemistry (IHC) images based on a previous report [152]. Briefly, DAB- 
and haematoxylin-stained IHC images of hCTR1 were deconvoluted to display DAB staining 
only (Fig. 5-2). The percentage of pixel counts were used to define the staining intensity as 
negative, medium positive or high positive of hCTR1 immunoreactivity (Fig. 5-2A). The full 
range of pixel intensity was defined as ranging from 0 to 255, where 0 represents the darkest 
shade and 255 the lightest shade. A pixel-by-pixel analysis was conducted to produce a 
histogram, where the X-axis represents the pixel intensity (0-255), and the Y-axis indicates the 
pixel count. The pixel intensity values were stratified into four categories, namely, 0-60, 61-
120, 121-170 and 171-229, to represent high positive, positive, low positive or negative 
staining. Pixel intensities of >230 were excluded from the calculation because they represent 
largely background baseline values. The percentage of each category was then calculated based 
on the total pixel counts.  
The summary of the software program-generated percentages of high positive, positive and 
low positive was used to represent the category of high positive (>70%), medium positive (6- 
69%) and negative (<5%) staining of hCTR1 for each image. Three representative fields were 
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randomly selected from each tissue section and subjected to the semi-quantitative analysis as 
above described (Fig. 5-2B). The software-generated percentages for the different categories 
were used to calculate the final percentage of hCTR1 positivity for the tissue section, which 
was 76 ± 3.9% in the example sample and deemed as high positive (Tab 5-2).  We then applied 
the semi-quantitative analysis method to quantifying the expression of the Cu transporters 
hCTR1, ATP7A and ATP7B in normal and tumor tissues of colorectal cancer patients. 
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Figure 5-2. Semi-quantitative analysis of DAB stained immunohistochemical images of 
hCTR1 in tumor tissues of colorectal cancer patient 
A. Digitally scoring of deconvoluted DAB-stained IHC images of hCTR1 illustrating the 
negative, medium and high positive staining intensity defined by the percentage of pixel counts. 
B. Three randomly selected fields of each tissue section were used to represent a single tissue 
sample for semi-quantitative analysis. Standard immunohistochemistry was performed on 
paraffin-embedded tumor tissues using a rabbit anti-hCTR1 primary antibody and a goat anti-
rabbit secondary antibody, stained with DAB and haematoxylin. Colored columns in the DAB 
image profile represent the percentage of pixel counts scored as high (red), medium (yellow) 
and negative (green) levels. Mag. 40x. 
Table 5-2.  Semi-quantitative analysis of DAB-stained immunohistochemistry images for 
hCTR1 positivity in tumor tissues of human colorectal cancer  
Field 
Program-generated percentage (%) Total 
percentage         
(%) 
Mean ± SD    
(%) High 
positive 
Positive Low positive 
Field 1 0.003 3.6 72 76 
76 ± 4 Field 2 0.12 8.6 64 73 
Field 3 0.01 1.9 79 81 
 
5.3.3 Immunochemical findings 
Standard DAB immunohistochemistry was performed on paraffin-embedded sections of tumor 
tissues and matched normal tissues collected from six colorectal cancer patients. DAB-stained 
images were deconvoluted and analyzed using the semi-quantitative method as described 
above. Representative IHC image and the deconvoluted DAB stained images were shown for 
tumor and normal tissues of 6 individual patients (Fig 5-3 and S-1, 2, 3). The average of 
percentages of hCTR1, ATP7A and ATP7B staining of three randomly selected fields was 
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summarized in Tab 5-3. The staining of three transporters was limited to the areas of 
adenocarcinoma in tumor tissue and associated with crypts in normal tissue (Fig. 5-10). The 
combined average percentage staining for all 3 three transporters in the tumor tissues was 
significantly higher than that observed in the normal tissues (57.2 ± 11.4% vs 49.3 ± 9.6%, P 
= 0.03, paired t test). However, there was no significant variation in transporter expression 
when tumor and normal tissues were grouped together (P = 0.1083, ANOVA). 
The percentage of hCTR1 positive immunostaining in tumor tissues was determined as 35 ± 
4.9%, 41 ± 2.9%, 45 ± 1.8%, 74 ± 4.5, 53 ± 2.9%, 56 ± 3.7% for six colorectal cancer patients 
respectively. This indicates an approximately 2-fold difference between the lowest and highest 
hCTR1 expression in these samples.  Likewise, the percentage of positive hCTR1 
immunostaining in normal tissues was determined as 34 ± 4.3%, 46 ± 2.7%, 65 ± 3.1%, 64 ± 
2.5, 41 ± 1.5%, 54 ± 2.6% for six patients respectively, which indicates about 2-fold difference. 
Comparison between matched tumor and normal tissues for hCTR1 showed no significant 
differences across six patients (50.7 ± 13.8% vs 51 ± 12.6%, P = 0.99, paired t test). 
The percentage of positive ATP7A immunostaining in tumor tissues was determined as 53 ± 
1.9%, 40 ± 7.9%, 57 ± 3.5%, 55 ± 6.1, 62 ± 3%, 64 ± 5.4% respectively for six colorectal 
cancer patients, indicating a slight difference between the lowest and highest ATP7A 
expression. Likewise, the percentage of positive ATP7A immunostaining in normal tissues 
was determined as 49 ± 2.1%, 45 ± 3.7%, 50 ± 2.6%, 51 ± 2, 44 ± 2.5%, 32 ± 2.3% respectively 
for six patients, indicating a ~1.7-fold difference between lowest and highest expression levels. 
Tumors also showed higher expression of ATP7A, although this was not statistically 
significant (55.3 ± 8.5% vs 45.3 ± 7%, P = 0.123, paired t-test).  
The percentage of positive ATP7B immunostaining in tumor tissues was determined as 69 ± 
2.5%, 65 ± 1.4%, 55 ± 4.1%, 73 ± 4.3, 63 ± 4.5%, 69 ± 2.1% respectively for six colorectal 
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cancer patients, indicating a slight difference between the lowest and highest ATP7B 
expression.  Likewise, the percentage of positive hCTR1 immunostaining in normal tissues 
was determined as 35 ± 2.9%, 53 ± 3.3%, 50 ± 3%, 59 ± 1.4, 57 ± 1.7%, 57 ± 3.8% respectively 
for six patients, indicating a ~1.7-fold difference between lowest and highest expression. 
Tumor tissues had significantly higher ATP7B percentage staining than those in the matched 
normal tissues (65.7 ± 6.3% vs 51.8 ± 8.9%, P = 0.0234, paired t test). 
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Figure 5-3. Representative immunohistochemical images of hCTR1, ATP7A and ATP7B 
in tumor and the matched normal tissues  
A. The expression of hCTR1 in tumor and normal tissue. B. The expression of ATP7A in 
tumor and normal tissue. C. The expression of ATP7B in tumor and normal tissue. Tumor and 
matched adjacent normal tissues were collected from six colorectal cancer patients, processed 
using standard DAB-based immunohistochemistry and counterstained with haematoxylin. 
DAB-IHC images were deconvoluted and analyzed using a semi-quantitative method to 
acquire the percentage of pixel intensity and counts of immunoreactivity. Mag. 40x.
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Table 5-3.  The expression of copper transporters in human colon samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, P < 0.05 compared to value of normal for ATP7B
Patient No. 
hCTR1 ATP7A ATP7B 
Tumor Normal Tumor Normal         Tumor Normal 
1 35 ± 4.9 34 ± 4.3 53.3 ± 1.9 49.3 ± 2.1 69 ± 2.5 35 ± 2.9 
2 41 ± 2.9 46 ± 2.7 40.2 ± 7.9 45.2 ± 3.7 65 ± 1.4 53 ± 3.3 
3 45 ± 1.8 65 ± 3.1 57.1 ± 3.5 50.3 ± 2.6 55 ± 4.1 50 ± 3 
4 74 ± 4.5 64 ± 2.5 54.9 ± 6.1 51.1 ± 2 73 ± 4.3  50 ± 1.4 
5 53 ± 2.9 41 ± 1.5 62.2 ± 3 43.7 ± 2.5 63 ± 4.5 57 ± 1.7 
6 56 ± 3.7 54 ± 2.6 63.9 ± 5.4 32.3 ± 2.3  69 ± 2.1 57 ± 3.8 
Mean ± S.D 50.7 ± 13.8 51 ± 12.6 55.3 ± 8.5 45.3 ± 7      65.7 ± 6.3*         51.8 ± 8.9 
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5.4 Discussion  
In this chapter, we have systematically studied the expression of Cu transporters hCTR1, 
ATP7A and ATP7B in tumor tissues of colorectal cancer patients. All of these three 
transporters were expressed in tumor tissues with significant differences between matched 
tumor and normal tissues for some colorectal cancer patients.  
We investigated the expression of Cu transporters in tumor tissues of colorectal cancer patients, 
in comparison to matched adjacent normal colonic tissues using a semi-quantitative DAB-
based immunohistochemistry method. Interestingly, the expression in colorectal cancer tumor 
tissues was largely in consistent with that in colorectal cancer cells. hCTR1 is widely expressed 
in tumor tissues of all six patients. This finding is consistent with previous reports that hCTR1 
is expressed in tumor samples of all 75 patients with colorectal cancer [101], [51]. The function 
of hCTR1 in colorectal cancer is unclear at present but may be related to the higher demand of 
copper during development and metastasis of this cancer type [195]. 
In the meantime, we detected a similar level of hCTR1 expression in normal colonic tissues in 
all six patients. hCTR1 immunoreactivity was strongly associated with epithelia of the 
enterocytes in the crypts. In a previous study, hCTR1 is expressed in human colon mucosa in 
about 16 of 42 cases using immunohistochemistry [100]. The higher positive rate of hCTR1 
expression detected in our samples may result from the different sensitivity of methods used 
to quantity hCTR1. mRNA transcripts of hCTR1 were also found in colon tissues of human 
[208] and zebrafish [209]. hCTR1 may function to absorb Cu and other nutrients across the 
colonic mucosa,  which is complementary to the absorptive function of the small intestine 
[210]. Moreover, the variation of hCTR1 expression levels in normal colon tissues may 
indicate that hCTR1 expression is influenced by patient’s age, gender or other factors [54].  
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We compared the expression levels of hCTR1 between normal colon tissue and CRC due to 
the importance of copper for the development of CRC. This study is the first where hCTR1 
expression in normal tissue was compared to matched CRC tissue with a quantitative and 
objective IHC profiling software. While Holzer et al reports that the frequency positive hCTR1 
expression increases with the clinical staging of CRC [100], we found that hCTR1 was not 
elevated in CRC cancers. The observation that hCTR1 was down regulated in some CRC 
cancer samples compared to the normal counterpart provides an opportunity to use Cu 
chelators to enhance the cytotoxicity of OXL by up regulating hCTR1.  
The expression of copper efflux transporters was confirmed in both malignant and normal 
colon tissues. ATP7A and ATP7B are copper-transporting P-type ATPases closely related to 
each other with respect to both structure and function. They are involved in both biosynthetic 
pathways and copper efflux in mammalian cells [54]. In addition to cancer tissues, ATP7B 
was widely detected in normal colon tissue, which is consistent with reports that ATP7B is 
also widely distributed in human liver, brain, heart and lung [211]. However, the function of 
ATP7B in normal colon samples is uncertain. Our results show ATP7B seems to be up 
regulated in colorectal cancer tissues, which is in line with reports from human gastric cancer 
[212], liver cancer [213] and ovarian cancer [214]. Here, again, the increased expression of 
ATP7B in colorectal tumor samples relative to that of normal colon samples could highlight 
its importance in colon carcinogenesis of colon tissues. 
In our study, we detected ATP7A in all colorectal cancer and normal colon tissue samples. 
These results are consistent with a report that ATP7A is ubiquitously expressed in the majority 
of tissues except for the liver [54], although a detailed understanding of the function of ATP7A 
in these tissues was beyond the aims of this study. ATP7A is reportedly up regulated in several 
cancers compared to their corresponding normal tissues [102-104] and is expressed in 8 of 34 
cases (23.5%) of clinical colon cancer specimens [102]. Therefore, detection of ATP7A in the 
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tumor tissues in our study did not come as a surprise. Perhaps colorectal cancer cells need more 
ATP7A to deliver copper to enzyme-synthetizing compartments or perhaps it involves in other 
important pathophysiological roles such as angiogenesis that is important for the progression 
of CRC [215].  
Lastly, it has to be pointed out that simultaneous expression of both ATP7A and ATP7B in 
colon tissues is not an uncommon phenomenon since this dual expression has also been 
described in other normal tissues, such as placenta, mammary gland, eye and lung [54]. At 
present however, it is not clear if they play complementary or synergistic roles in the 
translocation of copper across the membrane or if this process is essential to prevent 
cytoplasmic Cu-dependent toxicity.  
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Chapter 6 Expression of Copper Transporters in Colon 
Tissues of Winnie Mice with Chronic Colitis or Colonic 
Dysplasia 
6.1 Introduction 
The results of the previous chapter have demonstrated that ATP7B protein was up-regulated 
significantly in some colorectal tumor samples compared to normal tissue samples. Although 
the tumors also showed higher expression of ATP7A, this effect did not reach statistical 
significance. Nevertheless, these observations seem to support the hypothesis that copper or 
copper transporters may be involved in the development of colorectal cancer (Section 1.4.3), 
despite this assumption has not been tested in appropriate animal models to date. 
Chronic inflammation, in particular, ulcerative colitis (UC) is one of the important risk factors 
that can accelerate the transformation of colorectal mucosa to adenocarcinomas 
[151].  Dysplasia, as a precancerous condition is intertwined with both UC and colorectal 
cancer and is increasingly recognized as a diagnostic marker for colorectal cancer. In the 
context of intestinal inflammation, the development of colorectal cancer seems to follow a 
step-wise transition from normal mucosa to colitis, dysplasia and adenocarcinomas [216]. 
There is growing evidence that copper or copper-containing enzymes are correlated with 
inflammation and the development of malignancy of normal tissues. However, the role of 
copper transporters in these serial events has not been elucidated yet.  
The Winnie mouse model of colitis has been developed by chemically inducing a point 
mutation rather than a deletion of the Muc2 gene [151]. These mice display spontaneous 
inflammation in the distant colon at 6 weeks after birth and full colitis by the age of 16 weeks 
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[151]. In addition, Winnie mice show increased local production of IL-1b, TNF-a, and IFN-c 
as well as increased intestinal permeability in the distal colon, which are common pathological 
changes observed in human UC [217]. When exposed to DSS, most of Winnie mice will 
develop dysplasia, which is a precursor for colorectal cancer, suggesting of the suitability of 
this model as model of colorectal cancer development.  
Therefore, the overall goal of this chapter is to determine the roles of copper transporters in 
the development of colorectal cancer by studying their expression in colorectal tissues of wild-
type C57BL/6 mice, Winnie mice and dextran sulphate sodium (DSS)-treated Winnie mice 
that can reflect the normal, inflammatory, and precancerous condition of colon tissue as 
mentioned above. 
6.2 Experimental design 
6.2.1 Establishment of the colitis and dysplasia models 
We obtained colonic tissues from 10 Winnie mice with chronic colitis (n = 10), colonic tissues 
with histologically confirmed dysplasia from DSS-treated Winnie mice (n = 10) and colonic 
tissues from wild-type C57BL/6 mice (n = 10) as a normal tissue control (from Dr Raj Eri, 
School of Health Sciences, University of Tasmania). Winnie mice show spontaneous and 
inheritable intestinal colitis at the age of 6 weeks and full colitis by the age of 16 weeks because 
of a point mutation of the Muc2 gene [154]. When treated with the luminal agent DSS, most 
of these mice develop dysplasia, which is a precursor to colorectal cancer. Detailed information 
about these two animal models and how they were produced were described in Section 1.4.4. 
The Animal Ethics Committee of the University of Tasmania has approved this project (Ethics 
approval No: A0013576). 
6.2.2 Histological confirmation of chronic colitis and dysplasia in colon of mice 
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Histologically, chronic colitis is characterized with thickening of mucosa layer, irregularity or 
branching of crypts, presence and infiltration of inflammatory cells into submucosa [25]. 
Colonic dysplasia displays typical pathological changes such as focal presentation, loss of 
polarity of crypts and increased nucleus-to-cytoplasm ratio [27]. Therefore, H&E staining was 
performed on paraffin-embedded sections of colon tissues of Winnie, DSS-treated Winnie and 
wild-type C57BL/6 mice (See section of 2.9) to identify the nature of samples before 
undertaking following experiments.   
6.2.3 Characterization of the expression of mCTR1, ATP7A and ATP7B  
Standard DAB-based immunohistochemistry (IHC) was performed on paraffin-embedded 
sections of colon tissue using anti-mouse CTR1, ATP7A and ATP7BA primary antibodies and 
species-specific biotin-labeled secondary antibodies. The expression of the transporters was 
further quantified by analyzing the DAB-stained images using a semi-quantitative method as 
described previously (see Section 5.2.3). Briefly, IHC images of mCtr1 were deconvoluted to 
display DAB staining only. Pixel-by-pixel digital analysis of DAB-only images was conducted 
to produce corresponding histograms showing the percentages of immunostained areas based 
on the staining intensity.  The percentage of drug transporter immunostaining was calculated 
as the sum of percentages of high positive, positive and low positive staining that were 
generated using Image J software. Positive staining was defined based on the percentages as 
high (>65%), medium positive (30-64%), low positive (6-29%) and negative (<5%), 
respectively. Three fields were randomly selected for analysis and represented the final percent 
of positive staining for a specific tissue sample.  Comparison of expression levels was either 
made between tissue types or across transporter proteins. To properly illustrate these processes, 
a semi quantitative analysis was performed on DAB-stained IHC images of colon tissue for 
the Cu transporter mCTR1 (See Section 6.3.2). 
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6.3 Results 
6.3.1 Histological confirmation of chronic colitis in Winnie mice and colonic dysplasia in 
DSS-treated Winnie mice 
Standard H&E staining was performed on paraffin-embedded sections of colon tissues of 
Winnie, DSS-treated Winnie and wild-type C57BL/6 mice (Fig. 6-1A). Representative 
microphotographs illustrate abnormal pathological changes of chronic colitis in the colon of 
Winnie mice. These included a thickened mucosa, irregular, elongated or branching structure 
of crypts, loss of epithelium on the luminal side, infiltration of inflammatory cells into the 
lamina propia and submucosa, and crypt abscesses (Fig. 6-1A, b-f), when compared with 
normal colon tissue from C57BL/6 mice (Fig. 6-1A, a) 
A 
 
B 
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Figure 6-1. Representative colon microphotographs of histology of colitis of Winnie mice 
and colonic dysplasia in DSS-treated Winnie mice 
A. Histology of colitis in Winnie mice. (a) Normal distal colon tissue of wild-type C57BL/6 
mouse. (b-f) Distal colon tissue of Winnie mice with colitis displaying mucosal thickening (b), 
mucosal erosion (c), neutrophilic infiltration (d), branching crypts (e) and crypt abscesses (f), 
which were labeled or demarcated accordingly. B. Histology of colonic dysplasia in DSS-
treated Winnie mice. (a) Normal colon tissue. (b) Colon tissue of DSS-treated Winnie mouse 
with dysplasia displaying loss of polarity of crypt and increased nucleus-to-cytoplasm ratio. 
(c) Colon tissue of Winnie mouse with colitis showing elongated crypts and leukocyte 
infiltration into the mucosa and submucosa (asterisk). (d) Colon tissue of DSS-treated Winnie 
mouse displaying high extent of proliferation, focal dysplasia (arrows) and active chronic 
inflammation in mucosa featured by crypt fission, mucosal thickening and leukocyte 
infiltration (asterisks). Scale bars represent 50 μm. 
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In the DSS-treated Winnie mice, the representative microphotographs of H&E stained distal 
colon tissues displayed typical pathological changes of colonic dysplasia, such as focal 
presentation, loss of polarity of crypts and increased nucleus-to-cytoplasm ratio (Fig. 6-1B). 
Abnormal crypt structure was evident with enlarged or fission appearance, proliferation of 
epithelial nuclei and increased nucleus-to-cytoplasm ratio compared to normal colon tissue 
(Fig. 6-1B, c). In addition, inflammation was exacerbated in colon tissues of DSS-treated 
Winnie mice with thickening of crypts, increased infiltration of leukocytes into the mucosa and 
submucosa layers, large areas of erosion, fission or loss of crypts.  
6.3.2 Example of semi-quantitative analysis of DAB-stained images of 
immunohistochemistry  
An example is shown in Fig. 6-2 to illustrate the semi-qualitative analysis method for DAB-
stained IHC images of colon tissue for the Cu transporter mCTR1. Deconvoluted DAB-only 
images were processed to generate histograms of frequency of positively stained areas of colon 
tissues. The total percentages were calculated as 84%, 60%, 25.2% and 2.1%, which represent 
high, medium, low and negative staining of Cu transporter mCTR1 (Fig. 6-2A). As shown in 
Fig. 6-2B, three randomly selected fields in a tissue section produced reproducible percentages 
of mCTR1 positive staining as 56.7%, 56.4% and 57.5% (mean ± SD (57 ± 0.5%), therefore, 
this mCTR1 staining was categorized as medium for this particular tissue sample.  
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Figure 6-2. Semi-quantitative analysis of DAB stained immunohistochemical images of 
mCTR1 in colonic tissues of Winnie mice 
Standard DAB immunohistochemistry (IHC) was performed on paraffin-embedded colonic 
tissue sections using an anti-mCTR1 primary antibody and an anti-rabbit secondary antibody. 
Sections were counterstained with haematoxylin. A. Digitally scoring of deconvoluted DAB-
stained IHC images of mCTR1 illustrating negative, low, medium and high positive staining 
defined by the percentage of pixel counts. Colored columns in DAB image profiles represent 
the percentage of staining intensity as high (red), medium (yellow), low (blue) or negative 
(green) levels. B. Three randomly selected fields of a section represent a specific tissue sample 
for semi-quantitative analysis. Mag. 40x. 
We subsequently applied this semi-quantitative analysis to quantify the expression level of Cu 
transporter mCTR1, ATP7A and ATP7B in colonic tissues from Winnie mice of colitis, DSS-
treated Winnie mice and wild-type normal mice.  
6.3.3 Expression of copper transporters in mouse tissues  
mCTR1 immunoreactivity was detected in all colonic tissues of these mice but this staining 
was limited to the colonic crypts of Winnie mice and C56BL/6 mice. The overall percentage 
of positive mCTR1 immunostaining for all these samples was measured as 66 ± 13%, which 
was significantly higher than that of normal tissues (66 ± 13% vs 50 ± 7.9, P < 0.05). In Winnie 
mice exposed to DSS, mCTR1 staining was detected in all these colon samples (Fig. 6-3C). 
Strikingly, the overall staining level for mCTR1 was significantly reduced by 3 folds in DSS-
treated Winnie mice compared to that of untreated Winnie mice (23 ± 12% vs 66 ± 13,  P < 
0.05) (Fig. 6-3A and Tab 6-1). 
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Next, we analyzed the expression of ATP7A in colonic tissues collected from Winnie mice of 
colitis, DSS-treated Winnie mice and wild-type C57BL/6 mice using the same method used to 
quantify mCTR1 expression. Overall, ATP7A immunoreactivity was detected in all colonic 
tissues analyzed. The overall percentage of positive ATP7A immunostaining of all ten samples 
from DSS-treated mice was measured as 51 ± 9.7%, which was similar to that of normal colon 
samples (50 ± 15%). In Winnie mice, ATP7A staining was detectable in all these colon samples 
despite overall weaker expression intensity. The overall level of ATP7A expression was 
significantly reduced compared to that of untreated Winnie mice (20 ± 5.3% vs 51 ± 9.7%, P 
< 0.05) (Fig. 6-3B and Tab 6-1). 
Subsequently, we analyzed the expression of ATP7B in colonic tissues collected from Winnie 
mice of colitis, DSS-treated Winnie mice and wild-type C57BL/6 mice with the same methods 
used to quantify mCTR1 and ATP7A. Overall, ATP7B immunoreactivity was detected in all 
colonic tissues of mice. The overall percentage of positive ATP7B immunostaining of all ten 
samples was measured as 64 ± 9.5%, which was similar to that of normal colon samples (66 ± 
4.9%). Immunohistochemistry was also performed on paraffin-embedded sections of 
dysplastic colon samples from ten Winnie mice exposed to DSS. ATP7B staining was 
detectable in all these colon samples despite weak expression. The overall level for ATP7B 
staining significantly reduced compared to untreated Winnie mice (11 ± 3% vs 64 ± 9.5%, P < 
0.05) (Fig. 6-3C and Tab 6-1) 
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Figure 6-3. Semi-quantitative analysis of representative DAB-stained images 
showing immunostaining of mCTR1, ATP7A and ATP7B in colonic tissues 
A. Immunostaining of mCTR1 in colonic tissues of normal mice, Winnie mice with 
chronic colitis and DSS-treated Winnie mice with colonic dysplasia. B.  
Immunostaining of ATP7A in colonic tissues of normal mice, Winnie mice with chronic 
colitis and DSS-treated Winnie mice with colonic dysplasia. C. Immunostaining of 
ATP7B in colonic tissues of normal mice, Winnie mice with chronic colitis and DSS-
treated Winnie mice with colonic dysplasia. Standard DAB immunohistochemistry was 
performed on paraffin-embedded colonic tissue sections using specific antibodies as 
mentioned in Section 2.1. Sections were counterstained with haematoxylin.  DAB-IHC 
images were deconvoluted and analyzed using a semi-quantitative method to acquire 
the percentage of pixel intensity and counts of immunoreactivity. Mag. 40x. 
Table 6-1.  The expression percentage of copper transporters in colonic tissues of 
mice 
*, P < 0.05 compared to values of normal mice; +, P < 0.05 compared to values of mCTR1. 
 
 
 
Group 
Percentage expression of copper transporters (Mean ±S.D, n=10) 
mCTR1 ATP7A       ATP7B 
Winnie + DSS            23 ± 12 *         20 ± 5.3 *        11 ± 3*, + 
Winnie            66 ± 13 *         51 ± 9.7 +        64 ± 9.5  
Normal            50 ± 8         50 ± 15        66 ± 4.9 + 
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6.4 Discussion 
Colitis-associated colorectal cancer is a chronic disease that normally takes 15-20 years 
to develop from inflammatory bowel disease over colonic dysplasia to adenocarcinoma 
[218]. The Winnie mouse model provides an opportunity to study the expression of 
copper transporters in colon tissues within a shorter time period. For the first time, this 
study observed that mCTR1 expression is elevated in colon tissues of Winnie mice 
compared to normal C57BL/6 mice, which supports our hypothesis that copper 
transporters play a role in the development of inflammatory bowel disease.  
Histological examination evaluated the severity of inflammation and the presence of 
neoplasia in the colon of Winnie and DSS-treated Winnie mice. Typical inflammation 
associated histological or structural changes were detected in all colon samples of 
Winnie mice, suggesting that this chronic colitis model recapitulates the main 
pathological features of the human disease [151]. Upon challenging with DSS, all 
examined samples showed low to medium-level dysplasia as well as signs of 
exacerbated inflammation of the colon wall. These results are consistent with another 
report that characterizes histological inflammation and dysplasia-related pathology in 
these two models [148]. 
Following confirmation of inflammation and dysplasia in colon samples, the expression 
of copper transporters was examined. mCTR1 expression was up regulated in colon 
tissues of Winnie mice but reduced in the precancerous colon tissues compared to the 
normal tissue samples. Our first result is in line with previous reports that CTR1 
expression is elevated in the eyes of patients with Eales disease, an idiopathic 
inflammatory disease [219] or chemical induced inflammation in rat liver [220]. A 
complete understanding of the mechanisms behind this phenomenon is beyond the 
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scope of this study, however, due to their wide involvement in several inflammation 
processes, copper or copper containing enzymes may be the key to explain this result. 
The second finding that mCTR1 was down regulated in dysplastic colon tissue is 
contradictory to the expected role of hCTR1 in the carcinogenesis of colorectal cancer 
as discussed in Chapter 5. Considering that copper can be pro-inflammatory, mCTR1 
down-regulation may be the result of the mucosa’s response to acute DSS-induced 
inflammation. On the other hand, there is evidence that DSS can suppress the 
transcription of a multitude of genes by directly inhibiting DNA polymerase activity 
[221]. Consequently, this down regulation could be a consequence of DSS itself and 
might have nothing to do with the carcinogenic process per se. Therefore, one should 
be cautious to extrapolate this finding to the human condition.  
Next, we compared the expression of the copper efflux transporters, ATP7A and 
ATP7B in colonic samples of Winnie mice with that of normal C57BL/6 mice. However, 
the overall expression of ATP7A or ATP7B was similar in colitis compared to normal 
tissue. The roles of copper efflux transporters in colon tissues under inflammatory 
conditions have not been studied yet. However, there is some evidence suggesting that 
copper efflux transporters might be altered under inflammatory conditions. Increased 
expression of ATP7A and trafficking of these proteins into cytoplasmic vesicles is 
observed in cultured BV-2 microglial cells in the presence of the pro-inflammatory 
agent interferon-gamma [222]. Mutation of ATP7B in Wilson disease is a well-known 
cause of severe inflammation in liver [127]. Perhaps copper efflux transporters are 
different from mCTR1 in the roles they play in the inflammation of colon.  
Given the numerous reports that ATP7A and ATP7B are up regulated in many human 
cancers [103], [63], we expected to see increased expression. However, we observed a 
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consistent reduction of AP7A or ATP7B in colonic samples of colonic dysplasia, 
similar to the response of mCTR1 in the same tissues. Consequently, the same 
limitations of DSS treatment postulated for mCTR1 expression could also apply for the 
expression levels Cu-efflux transporters. Therefore, these results should be interpreted 
with caution, especially when comparing them to the human condition.  
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Chapter 7 General Discussion 
The results described in this thesis demonstrate that hCTR1 regulates the transport and 
cytotoxicity of OXL in colorectal cancer cells, and that pharmacologically modulating 
hCTR1 protein level with some commonly used copper chelators could be used to 
enhance OXL cytotoxicity. We gained some preliminary understanding about the 
expression of copper transporters in colorectal cancer and in the precancerous stages 
including inflammation and dysplasia. In this thesis, recombinant and wild-type 
colorectal cancer cells were used as cellular models. Human colorectal tissues from 
colorectal cancer patients provided the clinically relevant biological samples. Winnie 
mice and DSS-treated Winnie mice were employed as animal models of chronic 
intestinal colitis and colonic dysplasia, respectively. 
Stable, recombinant expression of hCTR1 mRNA in colon cancer cells was directly 
correlated with enhanced uptake of OXL and increased cytotoxicity compared to empty 
vector transfected control cells (Chapter 3). Clinically used copper chelators enhanced 
hCTR1 protein expression in CRC cell lines in a time-dependent manner. Pre-
incubation of resistant colorectal cancer cells with these copper chelators under the 
same experimental conditions sensitized these cells to OXL cytotoxicity. Our results 
also suggest that this effect is mainly transmitted by hCTR1-dependent mechanisms, as 
the utilized Cu chelators had little effect on the expression or localization of the copper 
efflux transporter ATP7A and ATP7B (Chapter 4). Abundant expression of hCTR1 was 
detected in human colorectal cancer tissues. In contrast to hCTR1, we observed that 
ATP7B protein was up regulated in some of tumor samples compared to the normal 
tissues (Chapter 5). The percentage of mCTR1 staining increased in colonic tissues of 
Winnie mice, but decreased in tissues of dysplasia model compared to that of the normal 
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colon tissues. ATP7A and ATP7B expression were unaltered in tissues of colitis but 
decreased significantly in colonic tissues of dysplasia (Chapter 6). 
Taken together, these findings suggest that copper transporters are widely expressed in 
colorectal cancers and they are not only responsible for uptake and cytotoxicity of OXL 
but may also be involved in the development of colorectal cancer itself.  
In this chapter, the results are divided into four categories: copper uptake transporter 
hCTR1 and the uptake of OXL, the synergistic effect of copper chelators with OXL in 
the treatment of colorectal cancer, the differential expression of copper transporters in 
colorectal cancer tissues, and the expression of copper transporters in colon tissues of 
Winnie mice with chronic colitis or colonic dysplasia. Potential implications of each 
result and their possible applications are also discussed, which is based on the results 
of this thesis and previously published reports. Finally, future research directions that 
have arisen based on the results of this thesis are described at the end of this chapter. 
7.1 Human Cu uptake transporter 1 contributes to the uptake and cytotoxicity of 
oxaliplatin 
The precise mechanisms of OXL resistance are still not well characterized yet, despite 
decades of intensive studies. A common view is that tumor cells may become resistant 
to OXL via multiple approaches including alterations in cellular transport and 
accumulation, detoxification, cell death, DNA damage response and repair, and 
epigenetic mechanisms [29,30]. Of all these complex factors that may affect the 
pharmacology of OXL, the pathways that control the cellular accumulation of OXL are 
increasingly accepted as the main factor to affect the anticancer efficacy of OXL 
[47,49]. OXL is a polarized molecule and this chemical property determines it enters 
cancer cells mainly through a transporter-mediated routes rather than passive diffusion 
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as some have proposed [42]. Over the years, many membrane transporters such as 
copper transporters, solute carrier transporters, and the ABC family of drug efflux 
transporters have been implicated in the accumulation of OXL in cancer cells or tumor 
tissues. These transporters have been demonstrated to either control the influx of OXL 
as uptake transporters, or regulate the efflux of OXL as efflux transporters [34] (see 
section 1.2.4 on page 26). Since the first report implicating hCTR1 in the transport of 
platinum drugs in yeast [146], there have been multiple lines of evidence supporting 
that hCTR1 regulates the cytotoxicity of cisplatin by affecting drug uptake [148].  
Reports have been published about the roles of  the copper exporters ATP7A and 
ATP7B in cisplatin resistance by enhancing its efflux [150]. Similarly, it seems that 
copper transporters may also regulate cellular accumulation and cytotoxicity of other 
platinum drug such as carboplatin [64]. 
Herein, it can be speculated that copper transporters may also be implicated in the 
transport of OXL, as these drugs are structural analogues of cisplatin. Results from 
early studies have revealed the positive role of CTR1 in OXL uptake in some non-
cancerous cellular models such as yeast cells, mouse embryonic cells and HEK293 cells 
(Page 27-28, section 1.3.1.1). However, direct evidence linking copper transporters and 
OXL transport in colorectal cancer is still missing.  
The first finding in this thesis is the link between hCTR1 expression and OXL uptake 
in recombinant colorectal cancer cells. Transfection of hCTR1 into colorectal cancer 
cells resulted in increased sensitivity of cells to copper and OXL (see section 3.3.2 on 
page 68, and section 3.3.3 on page 70). The study using special fluorescence probe 
FDCPt1 demonstrated the direct contribution of hCTR1 to the cellular uptake of OXL 
in these cells (see section 3.3.4 on page 73). These result support previous reports that 
also describe a positive role of recombinant hCTR1 in OXL uptake in other cell models 
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[47,49]. The extent to which overexpression of hCTR1 can enhance OXL uptake is 
variable between different studies. This difference is likely a consequence of different 
transfection regimens, different plasmid backbones, stable clone selection and cell 
types in general that likely alter achievable overexpression levels. In addition, the 
efficiency of hCTR1 to transport OXL may be also different among different forms of 
recombinant hCTR1. However, it is likely that in addition to hCTR1, other mechanisms 
and transporters are involved in the uptake of OXL, since mouse hCTR1 knockout 
fibroblasts still show some OXL accumulation [42].  
Although we have proved the hypothesis that hCTR1 mediates the transport of and 
OXL in colorectal cancer cells, the exact mechanisms by which hCTR1 mobilize OXL 
into cells have not been fully understood yet. In fact, it is still not clear about the precise 
mechanisms by which cisplatin is transported across the plasma membrane by hCTR1. 
Although, it has been suggested that cisplatin, similar to copper, is translocated into 
cellular compartments through the methionine residues in the putative hCTR1 pore 
[160], direct evidence at molecular level is still lacking. In addition, some studies show 
these two anti-cancer platinum analogues differ a lot in the ways they interact with 
hCTR1 [72]. Given the bulky size of OXL molecule and the bi-dente structure, the pore 
of hCTR1 trimer is not larger enough to translocate OXL towards cells, even though 
OXL has a strong tendency to bind with sulfa-containing motifs in the hCTR1 molecule 
[70].  
Lastly, it should be pointed out that the translational value of this study using 
recombinant cells is limited. While the transfection technique used in our experiments 
is able to assess the role of hCTR1 in vitro, it is clearly associated with some drawbacks 
such as low transfection efficiency in vivo, risk of viral infections to the host, and lack 
of tumor specificity [224]. Moreover, the high endogenous levels of hCTR1 protein in 
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DLD-1 cells determine that there is a limitation to how much the hCTR1 gene can be 
overexpressed in this cell line via transfection. In contrast, hCTR1 is overexpressed by 
80 folds in the small cell lung cancer cells which have modest endogenous hCTR1 
expression after transfection [64].  
7.2 Cu chelators enhance the cytotoxicity of oxaliplatin 
Cu chelators have been used widely in the treatment of many human diseases including 
cancers, copper disorders such as Wilson and Alzheimer’s diseases. The anti-cancer 
effect of Cu chelators as demonstrated in ovarian cancer, breast cancer, liver cancer, 
leukemia, and prostate cancer is mainly through the inhibition of angiogenesis [228, 
229].  
Reports about the application of copper chelators in colorectal cancer are rare yet still 
show promising therapeutic potential. ATTM in combination with irinotecan and 
florouracil improve the overall response rate after treatment by 25% and the median 
time to progression by 6 months than irinotecan or florouracil alone [230]. This 
synergism with these chemotherapies is in part attributable to the inhibitory effect of 
ATTM on angiogenesis of the tumour. TPEN, another copper chelator, selectively 
induces cell death in HCT116 colon cancer cells without affecting the viability of non-
cancerous colon or intestinal cells. Consistently, TPEN exhibits robust anti-tumour 
activity in mouse model of colorectal cancer [231]. 
In addition, copper chelators have the potential to increase the expression of hCTR1 
and this property has been utilized to enhance the efficacy of platinum anti-cancer drugs 
in many chemo-resistant cancers. For example, the literature has reported the 
potentiation of uptake and cytotoxicity of platinum anticancer drugs in ovarian cancer 
cells following preincubation with copper chelators, ammonium tetrathiomolybdate 
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(ATTM), D-penicillamine (D-P), and an experimental Cu-chelating compound called 
bathocuprione disulfonate (BCS) [73], the enhancement of anti-tumour activity of 
cisplatin in mouse xenograft model of small cell lung cancer cells, following exposure 
to D-P [225,226] and the synergistic effect of ATTM on antitumor activity of cisplatin 
in the HPV16/E2 mouse model of cervical cancer model [225]. Furthermore, trientine 
was reported to resensitize terminal ovarian cancer patients to carboplatin with clinical 
responses in 4/5 patients [227].   
However, the effect of copper chelators on the expression of hCTR1 and the possibility 
of using it enhance the uptake of oxaliplatin have not been studied in colorectal cancer 
cells. Given the role of hCTR1 in OXL uptake and the abundant baseline expression of 
hCTR1 as demonstrated in both colorectal cancer cells and tissues, we therefore 
adopted pharmacological approach to target hCTR1 with copper chelators to increase 
the sensitivity of colon cancer cells to OXL-containing chemotherapies. 
In the work presented in this thesis, three different copper chelators were used, that 
included the experimentally used BCS and the clinically used ATTM, and D-P. BCS 
does not enter the plasma membrane but it prevents copper entry into cells by forming 
stabilized extracellular copper complexes. D-P binds to intracellular copper and 
facilitates its excretion out of cells. ATTM forms a ternary complex with copper ions 
and proteins, making copper unavailable to cells [225, 226]. Despite the different 
mechanisms of action, these chemicals consistently up regulated the expression of 
hCTR1 protein in colorectal cancer cells in a time-dependent way, which implies a 
common copper-dependent regulatory mechanism to control hCTR1 levels in 
colorectal cancer cells (see Fig. 4-10 and Fig. 4-11 from page 97 to page 102). Our 
results in this regard seem to correlate well with the reports showing that these copper 
chelators can be used to enhance the expression of hCTR1 in ovarian cancer and small 
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cell lung cancer cells [73]. However, we noticed a difference in the magnitude by which 
hCTR1 was upregulated by copper chelators. For example, hCTR1expression was 
increased by around 9-15 folds in ovarian cancer cells (OVACAR3 and SKOV3), which 
was in contrast to the approximately 40% increase in hCTR1 expression in what cells 
in our study. Similar to our results, a lower increase of about 50% was observed in 
ovarian cancer cells (59M and GROV1) [71]. Since the former cell lines have higher 
baseline levels of hCTR1 than the latter counterparts [71]. This discrepancy could be 
attributed to the difference in basal expression of endogenous hCTR1. All these results 
seem to suggest that the strategy of using copper chelators to enhance OXL uptake 
works better in colorectal cancer cells with lower basal hCTR1 expression. 
Despite the observation that both DLD-1 and SW620 cell achieved around 30% 
increase in hCTR1 expression with copper chelators, subsequent studies showed that 
pre-incubation of these cells with chelators significantly potentiated cellular sensitivity 
DLD-1 cells to OXL but not for SW620 cells (see Fig. 4-12 on page 104), suggesting 
other mechanisms other than hCTR1 may exist to determine the cellular sensitivity to 
OXL.  
Strikingly, these chelators did not alter the expression patterns or density of the Cu 
efflux transporters ATP7A and ATP7B (see Fig. 4-13 on page 105 and 106, and Fig. 4-
14 on page 107), which suggests that the synergistic effect of Cu chelators with OXL 
is mainly mediated via modulating hCTR1 expression.  
Taken together, our finding in conjunction with previous reports suggest that copper 
chelators may be advantageous via multiple mechanisms that also include hCTR1-
mediated transport, as combination treatment with OXL in colorectal cancers.   
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7.3 The differential expression of Cu transporters in colorectal cancer cells and 
tissues 
Our data provided support to the idea that hCTR1 directly affects cellular sensitivity to 
OXL. These results warrant a systemic and integrated investigation of hCTR1 
expression in human colorectal cancers. In addition, copper or copper-containing 
enzymes seem to be elevated in colorectal cancer tissues compared to that of the normal 
tissues [132], [139]. This phenomenon supports the role of copper as micronutrient that 
is essential to the development and progression of many cancers including colorectal 
cancers [135]. The diagnostic and prognostic value of copper transporters has been 
shown in ovarian cancer and small cell lung cancer but has not been systematically 
studied in native colorectal cancers [62], [232]. In our study, the expression profiles of 
copper transporters were determined in four colorectal cancer cell lines that were 
selected to represent the genotypic and phenotypic diversity of colorectal cancer in vivo. 
Moreover, these cell lines derived from human primary tumours provide several 
advantages, such as sufficient supply of live cells, a high reproducibility of 
experimental results and low cost. In addition, this allowed us to directly compare the 
expression of copper transporters in vitro with their expression in human colorectal 
cancer tissues ex vivo.  Cell based studies provided for the first time the comprehensive 
information about transporter expression, including the cellular localization, the 
expression intensity, and the transcriptional levels. The abundant and consistent 
expression of hCTR1 in all tested cell lines may be one of reasons that can explain the 
vulnerability of CRC cancer to oxaliplatin treatment (see section 4.3.1.1 on page 84). 
However, since the observed expression levels represented baseline levels, there is an 
option to pharmacologically manipulate their expression with copper chelators. The co-
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expression of ATP7A and ATP7B with hCTR1 in these cells demonstrated again that 
these transporters work together to maintain copper homeostasis. The down regulation 
of hCTR1 in some tumour samples may suggest there is a need to apply copper chelator 
to target hCTR1 to achieve effect of OXL (see Table 5-3 on page 139). The relative up 
regulation of the immmuostaining of ATP7B in some of tumour tissues to normal 
tissues may imply its contribution to growth of cancer cells (see Table 5-3 on page 139). 
7.4 The expression of Cu transporters in colon tissues of Winnie mice with chronic 
colitis or colonic dysplasia 
Colitis-associated colorectal cancer seems to follow a step-wise transition from normal 
mucosa to colitis, dysplasia and adenocarcinomas [216]. Copper homeostasis may be 
altered in the transition from inflammation to adenocarcinomas [151]. The Winnie 
mouse model of colitis and colonic dysplasia offered us a unique opportunity to 
determine the expression of Cu transporters and their relationship with the precancerous 
conditions of colonic tissues. 
In our study, we firstly observed that copper mCTR1 seems to be up regulated in the 
inflammation of colon mucosa from Winnie mice model of chronic colitis. While we 
did not observe altered levels of copper efflux transporters during colitis in the colon 
of Winnie mice (see Table 6-1 on page 156), there is still the possibility that their 
localization may be altered. This finding is in accordance with the previous reports that 
suggest either copper levels or copper-containing enzymes are increased in human 
colon tissues with inflammation [121], [126]. Although the causality of this observation 
is unknown yet, our results suggest that there is a possibility to treat intestinal colitis by 
pharmacologically targeting the different components responsible for copper 
homeostasis such as copper transporters, copper or even copper-containing enzymes.  
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We noticed that copper transporter expression was consistently reduced in colon tissues 
of DSS-treated Winnie mice with dysplasia (see Table 6-1 on page 156), This finding 
is contradictory to the reported phenomena that copper or copper-containing enzymes 
rise in different types of cancers including colorectal cancer. At present it is unclear 
why copper transporter expression was consistently reduced in the dysplastic colon 
tissues but suspect is that this could be a non-specific effect of the DSS treatment and 
unrelated to tumorigenesis.  
7.5 Future directions 
In the future it will be essential to understanding how hCTR1 interacts with OXL at the 
molecular level to transport OXL into cancer cells. This project will be challenging and 
may require coordinated effort of research teams across many disciplines including 
crystallography, biochemistry, genetics and even analytical chemistry. Perhaps a more 
practical approach would be to validate our main result in an in vivo colorectal cancer 
model that has been genetically altered to provide a range of defined levels of hCTR1 
expression. This tumor model would be also useful to test the translational value of our 
second finding with regards to the effect of copper chelators on hCTR1 expression in 
vivo. 
However, systemic exposure with copper chelators may cause adverse effects in human 
cancer patients [74], therefore, direct targeting hCTR1 in tumor tissues with tissue-
specific transfection technique (in situ gene transfection technique) may be a strategy 
to avoid this drawback (233). 
The negative response of these two transporters towards OXL or copper treatment 
seemed to suggest that they are irrelevant for OXL resistance as previously reported 
[64]. However, considering the inconclusive roles of ATP7A or ATP7B as 
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demonstrated in platinum drug resistance (section 1.3.1.2), their contribution to OXL 
transport need to be explored in colorectal cancer cells with recombinant expression of 
ATP7A and ATP7B alone or in combination. If, in the future, they are tested to be the 
efflux transporters of OXL in colorectal cancer cells, perhaps they can be also targeted 
with pharmacological agents to enhance the effect of OXL. 
Alterations of colonic copper transporter expression under condition of colitis suggest 
that copper homeostasis is disturbed in the process of intestinal inflammation. However, 
the exact roles of copper or copper enzymes in this process are not well understood and 
need further research. One possibility would be to perform intervention studies with 
anti-inflammatory agents or by directly examining the interplays between copper and 
the pro-inflammation cytokines in the same colitis model. Once confirmed to play 
active roles in the intestinal inflammation, copper transporters can be targeted to 
prevent or even treat this disease.  
Finally, the unexpected finding that oxaliplatin can up regulate hCTR1 expression 
deserves further attention as similar observation has been made by other researchers 
investigating the effect of cisplatin on the expression of hCTR1 in ovarian cancer [70].  
Understanding the mechanisms behind may inform about a possible role of hCTR1 in 
the development of OXL resistance of colon cancer.  
7.6 Conclusion  
In conclusion, this thesis demonstrated for the first time that the hCTR1 might be one 
of many factors that influence the pharmacology of OXL, probably through mediating 
its transport in colorectal cancer cells. The finding that some commonly used Cu 
chelators are able to enhance the endogenous expression of hCTR1 in CRC cells, and 
their synergistic use with OXL against some resistant CRC cell lines can be utilized to 
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improve the anti-tumor activity of OXL-based chemotherapy. The abundant expression 
of hCTR1 in human colorectal cancer cells and tumor tissues highlighted the 
importance of copper in the development of colorectal adenocarcinoma, while the 
altered expression of Cu transporters in the precancerous colonic tissues of Winnie mice 
suggests that Cu homeostasis may be disturbed during the progression of chronic 
colonic inflammation towards colorectal carcinogenesis. 
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Figure S-1. Semi-quantitative analysis of representative DAB stained 
immunohistochemical images of hCTR1 in tumor and the matched normal tissues 
of four colorectal cancer patients  
Standard immunohistochemistry was performed on paraffin-embedded tumor and 
normal tissues using a rabbit anti-hCTR1 primary antibody and a goat anti-rabbit 
secondary antibody, stained with DAB and hematoxylin. The DAB-stained IHC images 
were then deconvoluted and digitally scored of hCTR1 to illustrate the negative, 
medium and high positive staining intensity defined by the percentage of pixel counts. 
Mag. 40x. 
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Figure S-2:  
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Figure S-2. Semi-quantitative analysis of representative DAB stained 
immunohistochemical images of ATP7A in tumor and the matched normal tissues 
of four colorectal cancer patients  
Standard immunohistochemistry was performed on paraffin-embedded tumor and 
normal tissues using a rabbit anti-ATP7A primary antibody and a goat anti-rabbit 
secondary antibody, stained with DAB and hematoxylin. The DAB-stained IHC images 
were then deconvoluted and digitally scored of ATP7A to illustrate the negative, 
medium and high positive staining intensity defined by the percentage of pixel counts. 
Mag. 40x. 
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Figure S-3:  
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Figure S-3. Semi-quantitative analysis of representative DAB stained 
immunohistochemical images of ATP7B in tumor and the matched normal tissues 
of four colorectal cancer patients  
Standard immunohistochemistry was performed on paraffin-embedded tumor and 
normal tissues using a mouse anti-ATP7B primary antibody and a goat anti-mouse 
secondary antibody, stained with DAB and hematoxylin. The DAB-stained IHC images 
were then deconvoluted and digitally scored of ATP7B to illustrate the negative, 
medium and high positive staining intensity defined by the percentage of pixel counts. 
Mag. 40x. 
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